NRx Pharmaceuticals (NRXP) 10-Q 14 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 13, 2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-38302
Entity Registrant Name	NRX Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2844431
Entity Address, Address Line One	1201 Orange Street
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19801
City Area Code	484
Local Phone Number	254-6134
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		83,919,554
Entity Central Index Key	0001719406
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Common Stock
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	NRXP
Security Exchange Name	NASDAQ
Common stock warrants
Title of 12(b) Security	Warrants to purchase one share of Common Stock
Trading Symbol	NRXPW
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,902	$ 20,054
Prepaid expenses and other current assets	4,187	5,741
Total current assets	13,089	25,795
Other assets	21	21
Total assets	13,110	25,816
Current liabilities:
Accounts payable	3,631	2,076
Accrued and other current liabilities	4,728	4,855
Accrued clinical site costs	575	914
Convertible note payable and accrued interest - short term	10,069	7,703
D&O insurance payable	314
Warrant liabilities	10	37
Total current liabilities	19,327	15,585
Convertible note payable and accrued interest - long term		2,822
Total liabilities	19,327	18,407
Common stock, $0.001 par value, 500,000,000 shares authorized; 83,919,554 and 66,442,989 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	84	67
Additional paid-in capital	242,533	230,339
Accumulated other comprehensive loss	(22)
Accumulated deficit	(248,815)	(222,997)
Total stockholders' (deficit) equity	(6,217)	7,409
Total liabilities and stockholders' (deficit) equity	13,110	25,816
Series A Convertible Preferred Stock
Current liabilities:
Preferred stock, $0.001 par value, 50,000,000 shares authorized; Series A convertible preferred stock, $0.001 par value, 12,000,000 shares authorized; 3,000,000 and 0 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	$ 3

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	83,919,554	66,442,989
Common stock, shares outstanding	83,919,554	66,442,989
Series A Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	12,000,000	12,000,000
Preferred stock, shares issued	3,000,000
Preferred stock, shares outstanding	3,000,000	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development expenses	$ 3,314	$ 4,129	$ 10,837	$ 12,571
General and administrative	2,494	5,012	12,344	21,876
Settlement expense			250
Total operating expenses	5,808	9,141	23,431	34,447
Loss from operations	(5,808)	(9,141)	(23,431)	(34,447)
Other (income) expenses:
Interest income	(119)	(95)	(420)	(119)
Interest expense	40		40	3
Change in fair value of convertible note payable	359		2,794
Change in fair value of warrant liabilities	(26)	37	(27)	(236)
Change in fair value of earnout cash liability				(4,582)
Total other (income) expenses	254	(58)	2,387	(4,934)
Net loss	(6,062)	(9,083)	(25,818)	(29,513)
Change in fair value of convertible note attributed to credit risk			22
Other comprehensive loss			22
Comprehensive loss	$ (6,062)	$ (9,083)	$ (25,840)	$ (29,513)
Net loss per share:
Basic	$ (0.07)	$ (0.14)	$ (0.35)	$ (0.45)
Diluted	$ (0.07)	$ (0.14)	$ (0.35)	$ (0.45)
Weighted average common shares outstanding:
Basic	81,946,957	66,449,593	74,114,180	65,532,409
Diluted	81,946,957	66,449,593	74,114,180	65,532,409

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY - USD ($) $ in Thousands	Common Stock	Preferred Stock Series A Preferred Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Beginning balance at Dec. 31, 2021	$ 59		$ 203,990	$ (183,243)		$ 20,806
Beginning balance ,shares at Dec. 31, 2021	58,810,550
Common stock and warrants issued, net of issuance costs	$ 8		22,972			22,980
Common stock and warrants issued, net of issuance costs (in shares)	7,824,727
Stock-based compensation			1,334			1,334
Common stock issued for consulting services			17			17
Common stock issued for consulting services (in shares)	6,037
Net loss				(13,448)		(13,448)
Ending balance at Mar. 31, 2022	$ 67		228,313	(196,691)		31,689
Ending balance ,shares at Mar. 31, 2022	66,641,314
Beginning balance at Dec. 31, 2021	$ 59		203,990	(183,243)		$ 20,806
Beginning balance ,shares at Dec. 31, 2021	58,810,550
Common stock and warrants issued, net of issuance costs (in shares)						7,824,727
Net loss						$ (29,513)
Ending balance at Sep. 30, 2022	$ 68		229,470	(212,756)		16,782
Ending balance ,shares at Sep. 30, 2022	67,641,314
Beginning balance at Mar. 31, 2022	$ 67		228,313	(196,691)		31,689
Beginning balance ,shares at Mar. 31, 2022	66,641,314
Stock-based compensation			987			987
Additional issuance costs in connection with Private Placement			(342)			(342)
Net loss				(6,982)		(6,982)
Ending balance at Jun. 30, 2022	$ 67		228,958	(203,673)		25,352
Ending balance ,shares at Jun. 30, 2022	66,641,314
Stock-based compensation			541			541
Additional issuance costs in connection with Private Placement			(28)			(28)
Restricted stock awards granted (in Shares)	1,000,000
Restricted stock awards granted	$ 1		(1)
Net loss				(9,083)		(9,083)
Ending balance at Sep. 30, 2022	$ 68		229,470	(212,756)		16,782
Ending balance ,shares at Sep. 30, 2022	67,641,314
Beginning balance at Dec. 31, 2022	$ 67		230,339	(222,997)		7,409
Beginning balance ,shares at Dec. 31, 2022	66,442,989
Common stock and warrants issued, net of issuance costs	$ 3		2,542			2,545
Common stock and warrants issued, net of issuance costs (in shares)	3,866,666
Change in fair value of convertible note attributed to credit risk					$ 106	106
Stock-based compensation			695			695
Net loss				(11,039)		(11,039)
Ending balance at Mar. 31, 2023	$ 70		233,576	(234,036)	106	(284)
Ending balance ,shares at Mar. 31, 2023	70,309,655
Beginning balance at Dec. 31, 2022	$ 67		230,339	(222,997)		7,409
Beginning balance ,shares at Dec. 31, 2022	66,442,989
Change in fair value of convertible note attributed to credit risk						(22)
Common stock issued as repayment of principal and interest for convertible note						982
Net loss						(25,818)
Ending balance at Sep. 30, 2023	$ 84	$ 3	242,533	(248,815)	(22)	(6,217)
Ending balance ,shares at Sep. 30, 2023	83,919,554	3,000,000
Beginning balance at Mar. 31, 2023	$ 70		233,576	(234,036)	106	(284)
Beginning balance ,shares at Mar. 31, 2023	70,309,655
Common stock and warrants issued, net of issuance costs	$ 10		5,567			5,577
Common stock and warrants issued, net of issuance costs (in shares)	9,670,002
Change in fair value of convertible note attributed to credit risk					(128)	(128)
Stock-based compensation			544			544
Common stock issued as repayment of principal and interest for convertible note			200			200
Common stock issued as repayment of principal and interest for convertible note (in shares)	408,673
Net loss				(8,717)		(8,717)
Ending balance at Jun. 30, 2023	$ 80		239,887	(242,753)	(22)	(2,808)
Ending balance ,shares at Jun. 30, 2023	80,388,330
Stock-based compensation			351			351
Preferred stock and warrants issued, net of issuance costs		$ 3	1,168			1,171
Preferred stock and warrants issued, net of issuance costs (in shares)		3,000,000
Common stock issued to settle GEM settlement liability	$ 1		249			250
Common stock issued to settle GEM settlement liability (in shares)	675,676
Common stock issued as repayment of principal and interest for convertible note	$ 3		779			782
Common stock issued as repayment of principal and interest for convertible note (in shares)	2,855,548
Adjustments to Additional Paid in Capital, Deferred Offering Cost Settlement			99			99
Net loss				(6,062)		(6,062)
Ending balance at Sep. 30, 2023	$ 84	$ 3	$ 242,533	$ (248,815)	$ (22)	$ (6,217)
Ending balance ,shares at Sep. 30, 2023	83,919,554	3,000,000

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY
Preferred, common stock and warrants issued, issuance costs	$ 27	$ 2,168	$ 351

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$ (25,818)	$ (29,513)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		4	3
Stock-based compensation		1,590	2,862
Change in fair value of warrant liabilities		(27)	(236)
Change in fair value of earnout cash liability			(4,582)
Change in fair value of convertible promissory note	$ 359	2,794		$ 505
Non-cash settlement expense		250
Increases (decreases) in operating assets and liabilities:
Prepaid expenses and other assets		1,554	(1,443)
Accounts payable		1,654	(1,519)
Accrued expenses and other liabilities		(466)	2,991
Net cash used in operating activities		(18,465)	(31,437)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of computer equipment		(4)	(11)
Net cash used in investing activities		(4)	(11)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of note payable			(518)
Repayment of convertible note		(2,288)
Repayment of insurance loan		(474)
Proceeds from issuance of insurance loan		786
Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs		1,171
Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs		8,122	22,610
Net cash provided by financing activities		7,317	22,092
Net (decrease) increase in cash and cash equivalents		(11,152)	(9,356)
Cash and cash equivalents at beginning of period		20,054	27,605	27,605
Cash and cash equivalents at end of period	8,902	8,902	18,249	$ 20,054
Non-cash investing and financing activities
Cash paid for interest		646
Issuance of common stock as principal and interest repayment for convertible notes	$ 782	982
Issuance of common stock warrants as offering costs		75	726
Issuance of common stock for settlement of accrued liability		$ 250	$ 17

Organization

Organization	9 Months Ended
	Sep. 30, 2023
Organization
Organization	1. Organization The Business On May 24, 2021 (“Effective Time”), we consummated the business combination (“Merger”) contemplated by the Agreement and Plan of Merger (as amended, the “Merger Agreement”), dated December 13, 2020, by and among our company (formerly known as Big Rock Partners Acquisition Corp. (“BRPA”)), NeuroRx, Inc., a Delaware corporation (“NeuroRx”), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of BRPA (“Merger Sub”), pursuant to which Merger Sub was merged with and into NeuroRx, with NeuroRx surviving the Merger. As a result of the Merger, and upon consummation of the Merger and other transactions contemplated by the Merger Agreement, NeuroRx became a wholly-owned, direct subsidiary of BRPA. Upon the closing of the Merger, we changed our name to NRX Pharmaceuticals, Inc., with the stockholders of NeuroRx becoming stockholders of NRX Pharmaceuticals, Inc. Unless the context suggests otherwise, references to “NRx Pharmaceuticals,” “NeuroRx”, “NRXP,” “we,” or the “Company” refer to NRX Pharmaceuticals, Inc. and, where appropriate, its subsidiaries. The Company is a clinical-stage pharmaceutical company which applies innovative science to known molecules to develop life-saving medicines through its wholly-owned operating subsidiary, NeuroRx. The Company's foundation product, NRX-101 (D-cycloserine/Lurasidone), for the treatment of bipolar depression in patients with suicidality, has been awarded Fast Track designation, Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support by the U.S. Food and Drug Administration (the “FDA”). NRX-101 is covered by multiple U.S. and foreign patents, including a Composition of Matter patent (U.S. Patent No. 10,583,138) that was transferred to NRx Pharmaceuticals by Glytech, LLC. ​ Operations ​ As disclosed during the quarter, the Company’s drug development activities have expanded from its original focus on development of NRX-101, a fixed dose combination of D-cycloserine (DCS) and lurasidone for the treatment of suicidal bipolar depression to encompass the development of NRX-101 for the treatment of Chronic Pain and Complicated Urinary Tract Infection (cUTI) and the development of intravenous ketamine (NRX-100) for the treatment of suicidal depression. These additional indications have been added as the Company has gained access to clinical trials data funded by governmental entities in France and potentially in the United States which has the potential to afford the Company potential safety and efficacy data on key indications at low cost to shareholders. ​ Development of NRX-101 for treatment-resistant suicidal bipolar depression ​ The Company is nearing completion of enrollment of the originally-targeted 70 participants in the Phase 2b/3 trial of NRX-101 in TRBD; enrollment will continue through November to increase study power. The target population is based on the Company’s January 2023 meeting with the FDA in which the Company was guided to expand its intended use of NRX-101 from the original population of patients with acute suicidality who might be treated in the hospital environment to the broader population of patients with subacute suicidal ideation (now described by the Company as Treatment-Resistant Bipolar Depression) who are treated in the outpatient setting. ​ Based on the guidance of the FDA and the Company’s completion of manufacturing for phase 3/commercial stage investigational product, the Company upgraded the ongoing clinical trial to a phase 2b/3 trial, the results of which have the potential to be used for registrational filings. ​ During the first half of 2023, the Company refined its ability to validate the psychometric ratings that are used to assess the efficacy endpoints for the clinical trial. The Company relies upon a team of veteran raters who both train independent site raters and monitor the technical quality of each rating. A standard was set of 90% or better congruence between the Company’s veteran rating team and site raters. This standard was met for all study participants whose ratings were obtained in their primary language and management believes that this standard can be maintained for the duration of the trial. In Q2 2023, the Company released research findings that demonstrate better than 94% congruence on the Montgomery Asberg Depression Rating Scale (MADRS), which constitutes the primary efficacy endpoint. As of the filing of this 10-Q, this data integrity standard has been maintained. ​ In April 2023, the Company contracted with 1nHealth to initiate a recruitment campaign that may cover up to 45 states in the U.S. to recruit sufficient participants for this enlarged trial. The Company has similarly broadened its relationship with Science 37, a contract research organization that conducts decentralized clinical trials, to enroll participants identified by the 1nHealth recruitment initiative and randomize them to be treated within the broadened clinical trial. 1nHealth has additionally engaged “The Mighty,” a voice-of-the-patient organization with national reach to publicize the clinical trial to the 800,000+ subscribers who have indicated a focus on bipolar depression and suicidality. ​ In Q1 2023, the Company announced the participation of Prof. Andrew Nierenberg, M.D., Head of the Massachusetts General Hospital (MGH) Dauton Family Center for Bipolar Treatment Innovation as the Principal Investigator of the clinical trial. The Company has now initiated clinical trial sites at Northwestern University (Chicago) and University of Texas, Austin, in addition to commercial research sites. ​ The Company has completed manufacture of all clinical supplies required for its ongoing clinical trials. This initiative is expected to yield stability data sufficient to support a shelf life in excess of two years at time of potential drug launch (should the clinical trials be successful). The completion of this manufacturing milestone may allow the Company to decrease ongoing expenditure associated with manufacturing and development of chemical manufacturing controls. Through the filing of this 10-Q, product stability has continued to support the targeted two-year shelf life at potential drug launch. ​ On June 2, 2023, the Company entered into an Exclusive, Global - Development, Supply, Marketing & License Agreement (the “License Agreement”) with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (collectively, “Alvogen”). 20-year During the term of the License Agreement, NRx is permitted to develop additional products containing D-cycloserine in combination with one or more other active antidepressant or antipsychotic ingredients for use outside of the field of treatment of bipolar depression with suicidality, such as in post-traumatic stress disorder (PTSD) or chronic pain in depression, in which case, if NRx wishes to license rights to develop or commercialize such additional products or indications, Alvogen has a right of first negotiation to obtain such a license. ​ Progress on NRX-100 (ketamine) . ​ During Q1 management met with the psychiatry division of the FDA to discuss paths to market for NRX-101 as monotherapy and as sequential therapy following stabilization with ketamine. The FDA indicated that treatment following ketamine would require data sufficient to file a New Drug Application for the use of ketamine as a stabilization agent. Currently, the FDA has limited data on file that demonstrates the safety and efficacy of ketamine. Accordingly, the Company has established a scientific collaboration with Prof. Marion Leboyer of Paris, France and Prof. Mocrane Abbar of Lyon, France in order to incorporate the results of a 156-person inpatient trial of intravenous ketamine vs. placebo for the stabilization of patients admitted for acute suicidality (the KETIS trial). The findings of the trial demonstrate a statistically significant reduction in both suicidality (the primary endpoint) and depression (the secondary endpoint) among patients treated with intravenous ketamine compared to those treated with placebo. ​ In Q3, the Company signed a data sharing agreement with the Centre Hospitalier Universitaire De Nîmes in France in order to permit deidentified patient level data to be transmitted by NRx to the FDA for regulatory purposes. The patient-level deidentified data have now been received by the Company and are being assembled in the electronic format required by the FDA. The Company has now negotiated access to similar patient-level data from an NIH-funded US-based clinical trial the findings of which confirm the KETIS trial. The Company believes that these multicenter, randomized prospective trials encompassing more than 240 participants, combined with randomized, prospective data on more than 200 US patients when submitted for review at a patient level will likely be sufficient to demonstrate preliminary safety and efficacy of intravenous ketamine in acutely suicidal patients. Data are expected to be transmitted to FDA by the end of Q4. ​ Submission of a New Drug Application for the use of ketamine is dependent upon submission of a manufacturing file documenting the manufacture of a presentation of ketamine suitable for single-patient use in the treatment of suicidal depression. In November 2023, the Company announced the signing of a development and manufacturing agreement with Nephron Pharmaceuticals (West Columbia, SC) to develop a single patient presentation of ketamine that is expected to overcome some of the formulation deficiencies of existing forms of ketamine (developed for anesthesia) and is expected to have diversion-resistant and tamper-resistant features. The company believes that this latter aspect is important because of the well-known uses of ketamine as a drug of abuse and as a vehicle for date rape. ​ The Company’s current timeline entails the submission of a New Drug Application for ketamine in the first quarter of 2024 with a targeted PDUFA date in Q4 2024. Nephron has considerable experience in the manufacture of ketamine products and, therefore, the Company anticipates that two-year shelf stability at launch may be able to be achieved with six months of real-time accelerated stability. ​ As with the NRX-100 development project, the Company does not anticipate funding this initiative with core NRx assets and is exploring structures for a new entity that would provide current and new investors with both capital appreciation and a royalty stream. In support of that initiative, the Company received a non-binding term sheet in November 2023 for $30 million of new investment capital to support the establishment of a new, publicly-traded entity the shares of which would be initially owned by NRx, current shareholders of NRx, and by new investors. Establishment of this entity is expected to be a topic of discussion at NRx’s upcoming annual meeting of shareholders. ​ New Therapeutic Targets: ​ The Company is exploring three new therapeutic targets for NRX-101 and related drugs: treatment of Chronic Pain, treatment of Urinary Tract Infection (UTI), and treatment of Post Traumatic Stress Disorder (PTSD). ​ Treatment of Chronic Pain: ​ The rationale for treatment of chronic pain with DCS is outlined in a 2016 scientific paper published by Schnitzer, et. al. and in the White Paper posted by the Company’s Scientific Leadership (Sappko, et. al.). In brief, DCS as an N-methyl-D-aspartate (“NMDA”) antagonist drug has demonstrated extensive nonclinical and early clinical efficacy in: (i) decreasing the response to nociceptive pain (i.e., pain triggered by pain receptors in the body) and (ii) decreasing craving for opioid drugs, with evidence that DCS is both nonaddictive and non-neurotoxic. In order to support its development of NRX-101 for treatment of chronic pain, the Company has licensed US Patent 8,653,120 from Apkarian Technologies and retained Prof. Apkar Vania Apkarian (the inventor) as a consultant to the Company. The Company believes that its ongoing composition of matter patents additionally apply to the use of NRX-101 in the treatment of chronic pain, as does its patent portfolio related to the treatment of fear memory with NRX-101. ​ In the course of its psychiatry-focused drug development program, the Company completed addiction studies, using standard self administered assays that demonstrate no potential for addiction from NRX-101 and its components. These findings are essential for consideration of NRX-101 as a potential treatment for chronic pain and distinguish NRX-101 from other NMDA antagonist drugs including ketamine and dextromethorphan. ​ The Company is awaiting results of a 200-person randomized prospective trial funded by the US Department of Defense (NCT 03535688) in which patients with chronic pain were randomly assigned to DCS 400mg/day vs. placebo. The investigators have identified primary completion of this trial as occurring in November 2023, with top-line results. Should these results support efficacy of D-cycloserine in the treatment of chronic low back pain, they are expected to provide a Breakthrough Therapy path towards treatment of chronic pain with DCS and DCS-containing medicines. ​ While awaiting these clinical trial results, the Company filed an Investigational New Drug (IND) application with the FDA and received a “Study May Proceed” letter for an IND-opening trial of NRX-101 in the treatment of Chronic Pain. The review by the FDA Division of Anesthesia, Analgesia, and Addiction Products identified no new non-clinical requirements beyond those already agreed to with the Division of Psychiatry Products, other than the need to extend certain animal safety studies to the longer (90 day) duration required for the treatment of chronic pain. Should the Department of Defense (DOD)-funded trial demonstrate efficacy, the Company anticipates that these data will also form a basis for a Breakthrough Therapy Designation filing. ​ At the initiative of the US Congress, the National Institutes of Health has established the multibillion dollar HEAL initiative (https://heal.nih.gov/research/clinical-research/eppic-net) combined with a national consortium of clinical trial sites (EPPICNET) to test innovative non-opioid medicines to treat Chronic Pain. The Company has submitted an application to EPPICNET for inclusion of NRX-101 in its clinical trial program. The Company anticipates that the HEAL initiative, additional DOD funding, and other non-dilutive sources of capital may be available, given the national focus on developing non-opioid, non-addictive pain medications. ​ Chronic pain affects more than 50 million American adults, compared to the approximately 3 million who report thoughts of suicide on an annual basis. There has been no new non-opioid class of drugs to treat nociceptive pain in the past two decades and NRX-101 is expected to be the first NMDA-antagonist drug to seek approval for this indication. Today, ketamine is used off label to treat nociceptive pain, despite its clear limitations (addiction, neurotoxicity, hallucination, and the need for IV administration.) Thus, should the DOD data provide encouraging findings, these findings may open a far larger market for NRX-101 than the originally-targeted psychiatry indications. ​ Treatment of PTSD: ​ The Company has previously identified the rationale for treating Post Traumatic Stress Disorder with NMDA antagonist drugs. Based on the near-term data associated with the use of DCS in chronic pain and recent in-licensing of US8653120, management has elected to apply available resources to the chronic pain indication in the near term. ​ Treatment of Urinary Tract Infection (UTI) and Urosepsis: ​ Although treatment of UTI is quite different from use of NRX-101 to treat Central Nervous System disorders, D-cycloserine was originally developed as an antibiotic because of its role in disrupting the cell wall of certain pathogens. This is true of a number of drugs used in psychiatry today. The use of D-cycloserine as an antibiotic fell out of favor in the 1970s because of the CNS effects caused by its NMDA-blocking properties and because of the widespread availability of first and second generation antibiotics. However, D-cycloserine remains unique among antibiotics in its near-100% excretion in the urine and the ability to achieve high urinary tract levels of D-cycloserine with oral administration. DCS is not widely used, in part, because of its known propensity to cause hallucination at therapeutically effective doses. The Company believes that the combination of DCS with a 5-HT2A antagonist in NRX-101 has the potential to treat antibiotic-resistant urinary tract infections with decreased propensity to cause unwanted CNS effects. ​ In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections and urosepsis (i.e., sepsis originating in the urinary tract) has resulted in a marked increase in ComplicatedUTI (cUTI), hospitalization, and death from urosepsis. The US Center for Disease Control and Prevention reports that more than 1.7 million Americans contract sepsis each year, of whom at least 350,000 die during their hospitalization or are discharged to hospice (CDC Sepsis Ref.). D-cyloserine (DCS) is currently approved for the treatment of tuberculosis and its label states that it “ may E. coli, Pseudomonas, and Acinetobacter ​ CRL has provided NRx with a research report performed under Good Laboratory Practices documenting in vitro data that we believe meet that published standards of the FDA Qualified infectious disease product (QIDP) program. Qualification for QIDP affords a sponsor five years of additional market exclusivity from FDA, regardless of patent status, together with Fast Track Designation and Priority Review. The Company believes that NRX-101 as an oral medication has the potential to demonstrate benefit in patients who would otherwise require intravenous third and fourth generation antibiotics. The Company believes that there are approximately 3 million patients per year who contract cUTI ​ Based on the in vitro study performed at CRL, the Company has submitted an Investigational New Drug application, requesting QIDP, Fast Track, and Priority Review designation. ​ As with the NRX-100 development project, the Company does not anticipate funding this initiative with core NRx assets and is exploring structures for a new entity that would provide current and new investors with both capital appreciation and a royalty stream. Should the Company succeed in serving 10% of the cUTI market, the Company believes that the potential royalty stream from NRX-101 has the potential to exceed $1 billion annually. ​

Liquidity

Liquidity	9 Months Ended
	Sep. 30, 2023
Liquidity
Liquidity	​ 2. Liquidity As of September 30, 2023, the Company had $8.9 million in cash. With the completion of enrollment in its clinical trial of NRX-101 for bipolar depression, the Company anticipates a reduction in its monthly cash expenditure. ​ On March 8, 2023, NRx Pharmaceuticals entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “March Investors”), providing for the issuance and sale of 3,866,666 shares of the Company’s common stock (“Common Stock”) and warrants to purchase up to 3,866,666 shares of Common Stock (the “March Investor Warrants”) in a registered direct offering priced at-the-market under Nasdaq rules for a purchase price of $0.75 per share (the “March Offering”). The March Investor Warrants have an exercise price of $0.75 per share, are exercisable beginning on September 8, 2023 (the “March Initial Exercise Date”) and will expire 5 years from the March Initial Exercise Date. The aggregate gross proceeds to the Company from the March Offering were approximately $2.9 million. The closing of the sale of these securities occurred on March 9, 2023. On June 6, 2023, the Company entered into a securities purchase agreement with certain institutional investors (the “June Investors”), providing for the issuance and sale of 9,670,002 shares of the Company’s Common Stock and warrants to purchase up to 9,670,002 shares of Common Stock (the “June Investor Warrants”). The Common Stock was issued in a registered direct offering for a purchase price of $0.65 per share (the “June Offering”) and the June Investor Warrants were offered pursuant to a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The June Investor Warrants have an exercise price of $0.6525 per share, are initially exercisable beginning six months following the date of issuance (the “June Initial Exercise Date”) and will expire 5 years from the June Initial Exercise Date. The aggregate net cash proceeds to the Company from the June Offering were approximately $5.71 million. ​ On August 28, 2023, the Company entered into a securities purchase agreement (the “Preferred Stock Securities Purchase Agreement”) with certain purchasers (the “August Investors”), pursuant to which the Company issued 3,000,000 shares of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”), and one (1) investor warrant (each an “August Investor Warrant”) for every share of Series A Preferred Stock issued. The shares of Series A Preferred Stock and the August Investor Warrants were offered pursuant to a private placement under Section 4(a)(2) of the Securities Act. Each August Investor Warrant entitles the holder to purchase one (1) share of Common Stock at a purchase price of $0.40 per share. The aggregate purchase price for each share of Series A Preferred Stock and associated August Investor Warrant was $0.40. The August Investor Warrants are exercisable starting on the six month ​ The Company’s ongoing clinical activities continue to generate losses and net cash outflows from operations. The Company plans to pursue additional equity or debt financing or refinancing opportunities in 2023 to fund ongoing clinical activities, to meet obligations under its current debt arrangements and for the general corporate purposes of the Company. Such arrangements may take the form of loans, equity offerings, strategic agreements, licensing agreements, joint ventures or other agreements. The sale of equity could result in additional dilution to the Company’s existing shareholders. The Company cannot make any assurances that additional financing will be available to it and, if available, on acceptable terms, or that it will be able to refinance its existing debt obligations which could negatively impact the Company’s business and operations and could also lead to a reduction in the Company’s operations. We will continue to carefully monitor the impact of our continuing operations on our working capital needs and debt repayment obligations. As such, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. The Company may raise substantial additional funds, and if it does so, it may do so through one or more of the following: issuance of additional debt or equity and/or the completion of a licensing or other commercial transaction for one of the Company’s product candidates. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary if the Company is unable to continue as a going concern. ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the balance sheet, statements of operations and cash flows for the interim periods presented. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. Use of Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the convertible note payable, earnout cash liability, stock options, warrants, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Certain Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements. Fair Value of Financial Instruments ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. (Refer to Note 11) Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions may, from time to time, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. Revenue Recognition Arrangements may include licenses to intellectual property, research services and participation on joint research committees. The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of research, the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. ​ The Company enters into contractual arrangements that may include licenses to intellectual property and research and development services. When such contractual arrangements are determined to be accounted for in accordance with ASC 606, Revenue from Contracts with Customers ​ The License Agreement with Alvogen as further discussed in Note 6 below is accounted for in accordance with ASC 606. In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following five steps: ​ i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations within the contract; and v. recognize revenue when (or as) the entity satisfies a performance obligation. ​ The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. ​ At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements typically consist of a license to intellectual property and research services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. ​ The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. ​ The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. ​ The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. ​ The Company’s revenue arrangements include the following: ​ Milestone Payments: At the inception of an agreement that includes milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. ​ Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). ​ Research Services: The Company is incurring research costs in association with the Alvogen agreement. After the First Milestone Payment (as defined in Note 6 below), the Company will be reimbursed for certain costs incurred related to reasonable and documented out-of-pocket costs for clinical and non-clinical development activities. The Company will recognize revenue for the reimbursed costs when the First Milestone Payment contingencies have been achieved and the Company has an enforceable claim to the reimbursed costs. ​ See Note 6, “Alvogen Licensing Agreement”, for further information on the application of ASC 606 to the License Agreement. ​ Research and Development Costs ​ The Company’s research and development expenses consist primarily of costs associated with the Company’s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. Convertible Note Payable ​ As permitted under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 825, Financial Instruments (“ASC 825”), the Company elects to account for its convertible promissory note, which meets the required criteria, at fair value at inception and at each subsequent reporting date. Subsequent changes in fair value are recorded as a component of non-operating loss in the consolidated statements of operations. The portion of total changes in fair value of the convertible note attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income in the accompanying Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. As a result of electing the fair value option, direct costs and fees related to the convertible promissory notes are expensed as incurred. ​ The Company estimates the fair value of the convertible note payable using a Monte Carlo simulation model, which uses as inputs the fair value of our common stock and estimates for the equity volatility and volume volatility of our common stock, the time to expiration of the convertible note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, we estimate our expected future volatility based on the actual volatility of our common stock and historical volatility of our common stock utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning six months from the issuance date. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default is estimated using Bloomberg's Default Risk function which uses our financial information to calculate a default risk specific to the Company. Stock-Based Compensation The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock- based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company’s common stock on the date of issuance. All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual’s role at the Company. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The fair value of the Private Placement Warrants (as defined below) was estimated using a Black Scholes valuation approach and the fair value of the Substitute Warrants (as defined below) was estimated using a modified Black Scholes valuation approach which applies a probability factor based on the probabilities of achieving earnout cash milestone and/or earnout shares milestone at each reporting period (see Notes 9 and 11). Modification of Warrants A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which may result in a reduction of additional paid-in capital, recognition of costs for services rendered, or recognized as a deemed dividend. Preferred Stock ​ In accordance with ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging – Contracts in an Entity’s Own Equity ​ Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, common stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss. The following outstanding shares of common stock equivalents were excluded from the computation of the diluted net loss per share attributable to common stock for the periods in which a net loss is presented because their effect would have been anti-dilutive. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2023 2022 2023 2022 Stock options ​ 2,548,849 2,654,579 2,548,849 2,654,579 Restricted stock awards ​ 666,667 ​ 1,000,000 ​ 666,667 ​ 1,000,000 Convertible preferred stock ​ 3,000,000 ​ — ​ 3,000,000 ​ — Common stock warrants ​ 33,021,591 17,521,753 33,021,591 17,521,753 Earnout Shares ​ — ​ 22,209,280 ​ — ​ 22,209,280 Earnout Shares from exercised Substitute Options and Substitute Warrants ​ — ​ 1,229,925 ​ — ​ 1,229,925 ​ Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. For the nine months ended September 30, 2023, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, that management believes materially affect the Company’s present or future results of operations, overall financial condition, liquidity or disclosures.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2023
Prepaid Expenses and Other Current Assets
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following at the dates indicated (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ December 31, 2022 ​ ​ (Unaudited) ​ ​ ​ Prepaid expenses and other current assets: ​ ​ Prepaid clinical development expenses ​ $ 1,999 ​ $ 1,966 Prepaid insurance ​ ​ 1,517 ​ ​ 3,167 Other prepaid expenses ​ ​ 665 ​ ​ 331 Prepaid legal expenses ​ — ​ 270 Other current receivables ​ ​ 6 ​ ​ 7 Total prepaid expenses and other current assets ​ $ 4,187 ​ $ 5,741 ​

Accrued and Other Current Liabi

Accrued and Other Current Liabilities	9 Months Ended
	Sep. 30, 2023
Accrued and Other Current Liabilities
Accrued and Other Current Liabilities	5. Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following at the dates indicated (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ December 31, 2022 ​ ​ ​ (Unaudited) ​ ​ ​ Accrued and other current liabilities: ​ ​ ​ ​ ​ ​ Other accrued expenses ​ $ 173 ​ $ 2,616 Accrued employee expenses ​ 739 ​ 923 Accrued research and development expenses ​ ​ 1,045 ​ ​ 974 Professional services ​ ​ 2,771 ​ ​ 342 Total accrued and other current liabilities ​ $ 4,728 ​ $ 4,855 ​

Alvogen Licensing Agreement

Alvogen Licensing Agreement	9 Months Ended
	Sep. 30, 2023
Alvogen Licensing Agreement
Alvogen Licensing Agreement	6. Alvogen Licensing Agreement On June 2, 2023, the Company entered into the License Agreement with Alvogen. The Company and Alvogen are referred to below individually as a “Party” and collectively as the “Parties.” License Grant Under the License Agreement, the Company granted Alvogen an exclusive (even as to the Company and its affiliates) worldwide, transferable and sublicensable license under certain intellectual property (including patents, know-how and trademarks) owned or controlled by the Company to develop (with certain limitations), manufacture, and commercialize the Company’s candidate therapeutic product, NRX-101, for the treatment of bipolar depression with suicidality. The term of the license is, on a country-by-country basis, 20 years from the first commercial sale of NRX-101 in such country, extendable by Alvogen for a two-year period upon its request made prior to the expiration of such 20-year period. During the term of the License Agreement, the Parties agree (on behalf of themselves and their affiliates) not to research, develop, seek or obtain any regulatory approval for the manufacturing, marketing, sale, or other commercialization of any product containing a fixed dose combination of D-cycloserine and lurasidone in the treatment of bipolar depression with suicidality, nor to authorize or assist (including by investing in or otherwise providing funding to) any third party to do so. ​ During the term, the Company is permitted to develop additional products containing D-cycloserine in combination with one or more other active antidepressant or antipsychotic ingredients for use outside of the field of treatment of bipolar depression with suicidality, such as in post-traumatic stress disorder (PTSD) or chronic pain in depression, in which case, if the Company wishes to license rights to develop or commercialize such additional products or indications, Alvogen has a right of first negotiation to obtain such a license. Term and Termination The License Agreement will remain in force until the earlier to occur of (i) 20 years following the first commercial sale of NRX-101 on a country-by-country basis (which may be extended for a two-year period at Alvogen’s request), and (ii) the date that the agreement is terminated under its early termination provisions. Early termination grounds include, subject to applicable cure periods, a material breach of agreement by the other Party, the bankruptcy or insolvency of the other Party, or a party’s reasonable belief that there is an unacceptable risk for harm in humans based upon preclinical safety data or the observation of serious adverse effects in humans. ​ In addition, Alvogen has the right to early termination if (i) the phase 2 study relating to NRX-101 is not completed and/or a successful read out from the study does not occur by March 31, 2024, or (ii) there is no completion of a Type B meeting with the FDA by March 31, 2024. Alvogen may also terminate upon sixty (60) days’ prior written notice to the Company at any time after the First Milestone Payment (as defined below) has been made. The Company also has the right to terminate the License Agreement if the current phase 2 study successfully concludes prior to March 31, 2024 and the Type B meeting with the FDA is completed by March 31, 2024 and Alvogen does not notify the Company within 60 days that it wishes to proceed with the development of NRX-101 or has not paid the First Milestone Payment. ​ Upon expiration or termination of the License Agreement, the intellectual property rights licensed to Alvogen under the License Agreement will revert to the Company, and all other rights and obligations of each of the parties will immediately cease, except for ant outstanding amounts owed as of the time of such expiration or termination. Upon termination, Alvogen will grant to the Company an exclusive irrevocable, perpetual, worldwide, royalty-bearing, sublicensable, transferrable license under the NDA rights to develop, manufacture, have manufactured, or commercialize the product in the field of bipolar depression with suicidality. Such reversion license would be granted by Alvogen to the Company in exchange for an equitable royalty payable by the Company to Alvogen that would be negotiated and agreed in good faith by the parties within 30 business days of such matter being presented to them. Milestone Payments In exchange for the license grant and the participation of the Company in the development, regulatory and commercial activities described below, Alvogen will pay the Company an initial $10 million cash payment upon the later of a positive data read-out from the Company’s ongoing Phase 2b/3 clinical trial and completion of the Type B meeting with the U.S. FDA (the “First Milestone Payment”). A second milestone payment of $5 million (the “Approval Payment”) is due upon Alvogen’s receipt of a copy of the FDA’s notice of NDA Approval for Product with the label indication for the treatment of bipolar depression with sub-acute or acute suicidality. Additional bonus milestone payments of increasing amounts up to $330 million will be payable upon the achievement of net sales targets measured over the trailing four quarters. Alvogen also will pay royalties (as described below) to the Company based on the net sales of NRX-101, with a reduction in royalties on a country-by-country basis upon expiration or termination of the Company’s patent protection on the NRX-101 composition. Royalties Subject to certain adjustments for sublicensing and other deductions, commencing on the first commercial sale of NRX-101, Alvogen has agreed to pay to the Company tiered royalties calculated on the basis of a percentage, ranging from the low to mid-teens, of annual net sales of NRX-101 measured over the trailing four quarters. In addition, if Alvogen sublicenses NRX-101 in any country other than the U.S. (in which the royalty rates described above will apply), Alvogen will pay the Company a percentage of any and all consideration received by Alvogen or its affiliates from sublicensing any of the rights granted. Development and Regulatory Activities Prior to payment of the First Milestone Payment by Alvogen to the Company, each Party has agreed to perform, at its own cost, certain development activities using diligent efforts and in accordance with applicable then-current good manufacturing and other applicable practices, laws and regulations, with the goal of supporting the preparation and filing of an NDA and obtaining regulatory approval for NRX-101. Until the payment of the First Milestone Payment, the Company has the sole right to control and responsibility for all regulatory matters relating to NRX-101, at its sole cost and expense, and the Company shall own all regulatory materials and own all worldwide regulatory approvals for NRX-101. ​ After the payment of the First Milestone Payment, Alvogen has the sole right and responsibility, at its cost and expense, for all regulatory matters relating to NRX-101, and Alvogen will own all regulatory materials and all regulatory approvals for the product in the licensed territory (and the Company will assign all of its rights in any regulatory materials to Alvogen). Each party has committed to reasonably cooperate with the other in carrying out the development and regulatory activities outlined in the development plan. In addition, Alvogen has agreed to fund the next registrational study of NRX-101 in the field of treatment of bipolar depression with suicidality. ​ Upon NDA approval of the product in the U.S., Alvogen has agreed to use diligent efforts to commercialize NRX-101 in the U.S., and, for 24 months following such approval, in other countries in the territory upon regulatory approval in each such country. If Alvogen does not commercialize NRX-101 in a country outside of the U.S. in the foregoing 24-month period, then the license may revert back to the Company with respect to such country and the Company would pay Alvogen tiered royalties in the low to mid-teens based on net sales of NRX-101 in such country. The Parties will also enter into a pharmacovigilance agreement to ensure compliance with safety reporting requirements of all applicable regulatory agencies globally with respect to the commercialization of NRX-101. Commercial Activities Under the License Agreement, the Company is responsible for and will control the manufacturing of the NRX-101 commercial product and for qualification and regulatory-related activities necessary for the manufacture of the product. The Parties intend to enter into a clinical supply agreement (and a related quality agreement) on reasonable and customary terms, in which the Company will supply Alvogen raw materials and/or finished product without any markup to the future supply price from the Company’s current contract manufacturer. Similarly, prior to initiation of the first Phase 3 study for the commercial product, the Parties will enter into a commercial supply agreement (and a related quality agreement) on reasonable and customary terms, in which the Company will supply Alvogen raw materials and/or finished product without any markup to the future supply price from NRx’s current contract manufacturer. At any time after NDA approval, Alvogen may elect to manufacture, fill and package the product itself or through a third-party supplier subject to the prior approval of the Company. In such case, the parties may also work together to establish a written manufacturing technology transfer plan to transfer manufacturing technology from the Company or the Company’s contract manufacturer to Alvogen or Alvogen’s designated third party supplier. The Company has agreed, as a part of its manufacturing commitments, to make available its qualified technical personnel to consult with Alvogen to complete transfer of the manufacturing technology if required under the License Agreement. ​ Following NDA approval, Alvogen will control and be responsible for advertising, marketing, promotion and marketing, pricing, and terms of sale for the product, all at Alvogen’s sole expense. Alvogen has committed to not shift, allocate, price or discount sales of the product for the purpose of reducing or disadvantaging the net sales of the product in order to reduce the payments owed by Alvogen to the Company under the License Agreement. ​ As of September 30, 2023, the Company has not achieved any milestones nor recognized any revenue associated with the License Agreement.

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt.
Debt	7. Debt Convertible Note On November 4, 2022, we issued an 9% redeemable promissory note (as amended, the “Note”) to Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”), for an aggregate principal amount of $11.0 million. The Note matures 18 months from the date of issuance subject to certain acceleration provisions. The Note carries an original issue discount of $1.0 million which was deducted from the principal balance of the Note. The net proceeds from the issuance of the Note was $10.0 million after transaction costs including the original issue discount, legal and other fees are included. The Company has the option to prepay the Note during the term by paying an amount equal to 110% of the principal, interest, and fees owed as of the prepayment date. The noteholder has the right to redeem up to $1.0 million of the outstanding balance of the Note per month starting six months after the issuance date. Payments may be made by the Company at their option in: (i) in cash with a 10% premium for the amount redeemed, (ii) by paying the redemption amount in the form of shares of Common Stock with the number of redemption shares being equal to the portion of the applicable redemption amount divided by the Redemption Conversion Price (as defined below), or (iii) a combination of cash and shares of common stock. The “Redemption Conversion Price” on any given redemption date equals 85% multiplied by the average of the two lowest daily volume weighted average prices per share of the common stock during the ten trading days immediately preceding the date that the noteholder delivers notice electing to redeem a portion of the Note. Beginning May 1, 2023, in the event (a) the daily dollar trading volume of the common stock of the Company on any given trading day is at least fifty percent (50%) greater than the lower of (i) the median daily dollar trading volume over the previous ten (10) trading days or (ii) the daily dollar trading volume on the trading day immediately preceding the date of measurement or (b) if the closing trade price on any given trading day is at least thirty percent (30%) greater than the Nasdaq Minimum Price, then the lender will be entitled to redeem over the following ten (10) trading days an amount of indebtedness then outstanding under the Note equal to twice the monthly redemption amount of $1.0 million solely by payment by stock, if permitted under the agreement, subject to the Maximum Percentage (as defined in the Note) and other ownership limitations. On March 30, 2023, the Company entered into an Amendment to the Note (the “First Amendment”), pursuant to which the Maximum Percentage was set at 9.99% of the number of shares of Common Stock outstanding on a given date. On July 7, 2023, the Company entered into Amendment #2 to the Note with Streeterville (the “Second Amendment”). Pursuant to the Second Amendment, the Company agreed to amend the redemption provisions of the Note to provide that the Company would pay to Streeterville an amount in cash equal to $1,800,000 on or before July 10, 2023, which amount was paid on July 10, 2023. In addition, the Company agreed that, beginning on or before July 31, 2023, and on or before the last day of each month until December 31, 2023 (the “Minimum Payment Period”), we would pay Streeterville an amount equal to $400,000 in cash (a “Minimum Payment”), less any amount satisfied by the delivery of Redemption Conversion Shares (as defined below). Notwithstanding the foregoing, Streeterville may also submit a request for redemption of up to an aggregate of $1,000,000 per month (the “Maximum Monthly Redemption Amount” and, together with the Minimum Payment Amount, the “Redemption Amounts”) in accordance with the terms of the Note. However, the portion of each Minimum Payment that is not satisfied by the delivery of Redemption Conversion Shares is the maximum amount of cash we will be required to pay in accordance with the Second Amendment during the Minimum Payment Period. The redemption of the Maximum Monthly Redemption Amount in excess of the Minimum Amount may be satisfied by the delivery of additional Redemption Conversion Shares. During the Minimum Payment Period, the Company is permitted to pay the Redemption Amounts in the form of shares of common stock of the Company (the “Redemption Conversion Shares”) calculated on the basis of the Redemption Conversion Price (as defined in the Note) without regard to the existence of an Equity Conditions Failure. Moreover, the Redemption Premium (as defined in the Note) will continue to apply to the Redemption Amounts. This amendment was deemed to be a debt modification in accordance with ASC 470, Debt, which will be accounted for prospectively. The modification does not result in recognition of a gain or loss in the consolidated statement of operations but does impact interest expense recognized in the future. ​ The Note contains certain Trigger Events (as defined in the Note) that generally, if uncured within five trading days, may result in an event of default in accordance with the terms of the Notes (such event, an “Event of Default”). Upon an Event of a Default, the Lender may consider the Note immediately due and payable. Upon an Event of Default, the interest rate may also be increased to the lesser of 18% per annum or the maximum rate permitted under applicable law. As of September 30, 2023, the Company was in compliance with the Note’s terms and there were no Events of Default. ​ Due to these embedded features within the Note, the Company elected to account for the Note at fair value at inception. Subsequent changes in fair value are recorded as a component of other income (loss) in the Consolidated Statements of Operations. ​ The Company estimates the fair value of the convertible note payable using a Monte Carlo simulation model, which uses as inputs the fair value of our common stock and estimates for the equity volatility and volume volatility of our common stock, the time to expiration of the convertible note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, we estimate our expected future volatility based on the actual volatility of our common stock and historical volatility of our common stock utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning six months from the issuance date. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default is estimated using Bloomberg's Default Risk function which uses our financial information to calculate a default risk specific to the Company. The discount to the principal amount is included in the carrying value of the Note. During 2022, the Company recorded a debt discount of approximately $1.0 million upon issuance of the Note for the original issue discount of $1.0 million. As a result of electing the fair value option, any direct costs and fees related to the Note was expensed as incurred. For the three and nine months ended September 30, 2023, the Company recorded a change in fair value of the Note of approximately $2.8 and $0.4 million, respectively, which was recognized in other income (expense) on the Unaudited Condensed Consolidated Statement of Operations as a result of the Company’s election of the fair value option. ​ During the three and nine months ended September 30, 2023, the Company made cash interest payments on the Note of approximately $0.5 million and $0.7 million, respectively, and issued shares of Common Stock as interest repayment of $0.1 million and $0.1 million, respectively. During the three and nine months ended September 30, 2023, the Company made cash principal repayments on the Note of approximately $1.7 million and ​ The following table presents the Note as of September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ December 31, 2022 ​ ​ (Unaudited) ​ ​ ​ Par value of the Note ​ $ 11,020 ​ $ 11,020 Debt discount ​ ​ (497) ​ ​ (1,000) Repayment of principal and interest ​ ​ (3,270) ​ ​ — Carrying value of the Note before current period change in fair value ​ ​ 7,253 ​ ​ 10,020 Fair value adjustment through earnings ​ ​ 2,794 ​ ​ 505 Fair value adjustment through accumulated other comprehensive income ​ ​ 22 ​ ​ — Total carrying value of Note ​ $ 10,069 ​ $ 10,525 ​ ​ ​ ​ ​ ​ ​ Convertible note payable - current portion ​ $ 10,069 ​ $ 7,703 Convertible note payable, net of current portion ​ $ — ​ $ 2,822 ​

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies
Commitments and Contingencies	8. Commitments and Contingencies Exclusive License Agreement The Company has entered into a License Agreement with Apkarian Technologies to in-license US Patent 8,653,120 that claims the use of D-cycloserine for the treatment of chronic pain in exchange for a commitment to pay milestones and royalties as development milestones are reached in the field of chronic pain. The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-101 to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids. As of September 30, 2023, the Company has recorded $0.2 million worth of expenses relating to the licensure of the patent recorded in R&D patents expense on the Condensed Consolidated Statements of Operations and Comprehensive Loss. ​ Operating Lease The Company leases office space on a month-to-month basis. The rent expense for the three and nine months ended September 30, 2023 was less than $0.1 million and less than $0.1 million, respectively. Sponsored Research Agreement with National Jewish Health On February 8, 2021, the Company entered into a Sponsored Research Agreement (“Research Agreement”) with National Jewish Health (“NJ Health”), a Colorado not-for-profit institution. Under the terms of the Research Agreement, the Company agreed to sponsor a research study at NJ Health relating to the impact of the Company’s' former product candidate Aviptadil on propagation of SARS-CoV-2 in alveolar type II cells in vitro (the “Study”). In return for performance of the Study under the Research Agreement, the Company has committed to pay NJ Health approximately $0.4 million upon finalization of the work. As of September 30, 2023, the Company has fully paid NJ Health the total committed amount under this agreement. ​ Relief Therapeutics Collaboration Agreement On September 18, 2020, the Company entered into a collaboration agreement (the “Collaboration Agreement”) with Relief Therapeutics for the clinical development and, if approved, the sale of Aviptadil. The Collaboration Agreement provides for funding by Relief Therapeutics of certain clinical trials, formulation and manufacturing of Aviptadil, as well as establishing specified sales territories for each party and share of the profits in those territories for “Product” as defined in the Collaboration Agreement. On October 6, 2021, Relief Therapeutics filed a lawsuit against the Company and its former CEO claiming that the Company failed to honor its obligations under the Collaboration Agreement, which was followed by a counter claim from the Company for breach and repudiation of the Collaboration Agreement by Relief Therapeutics. On November 12, 2022, the Company entered into a Settlement Agreement and Asset Purchase Agreement (“APA”) with Relief Therapeutics Holding AG and Relief Therapeutics International (the “Relief Parties”) to settle the outstanding lawsuit with respect to the Collaboration Agreement. Under the APA, the Company transferred to the Relief Parties all of the Company’s interest in ZYESAMI (or the “Product” as such term is defined in the Collaboration Agreement), including intellectual property, FDA applications, clinical trial data, drug and API inventory and certain contractual rights. The Company has agreed to refrain from developing any product for any indication that uses or otherwise exploits the Product without the Relief Parties’ consent. The Relief Parties have agreed to use commercially reasonable efforts to develop, market, and commercialize the Product, and have sole discretion to select the indications for which they will seek to develop the Product. Although the Company intends to monitor the progress of the Relief Parties under the APA and enforce the Company’s rights thereunder, there can be no assurances that the Relief Parties will be successful at commercializing the Product. Upon commercial launch of the Product by the Relief Parties or any of their affiliates, licensees or sublicensees (or upon authorization of use for any indication of the Product other than COVID-19), the Company is entitled to receive milestone payments in stages up to an aggregate amount of $13.0 million. The Relief Parties have also agreed to pay royalties to the Company on aggregate net sales of all Products, subject to a cap on royalty payments of $30.0 million in the aggregate. In addition, Relief is obligated to use commercially reasonable efforts to continue the Company’s existing Right to Try Program until December 2024. Mutual indemnity provisions in the APA will protect each party from any breaches of the settlement arrangements by the other party, provided, that the Company’s indemnity obligations will not start until the Relief Parties have begun making royalty or milestone payments to the Company, subject to certain exceptions. With respect to the Company, there is an indemnity threshold such that the Company will not be liable for any indemnity claims until such claims are in excess of $0.5 million (and then only for the amount above $0.5 million). The Company’s indemnity obligation is capped at $2.0 million with respect to breaches of representations and warranties and $3.0 million with respects to breaches of covenants or other agreements. Additionally, subject to certain exceptions, the Company’s indemnity obligations cannot exceed the amount that the Relief Parties actually pay to the Company for milestone and royalty payments. The parties closed the APA in December 2022 at which time all claims and counterclaims between the Company and the Relief Parties were dismissed with prejudice. Legal Proceedings From time to time the Company is involved in litigation, claims, and other proceedings arising in the ordinary course of business. Litigation and other disputes are inherently unpredictable and subject to substantial uncertainties and unfavorable resolutions could occur. Share Subscription Facility Agreement - GEM NeuroRx entered into a share subscription facility agreement (the “GEM Agreement”) with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (collectively, referred to as “GEM”) with a three-year term which expired in October 2022. The GEM Agreement was never activated because of differences between the Hong Kong law under which the agreement was drafted and US Securities law. On August 12, 2022, the Company received a demand for arbitration (the “Demand”) from GEM. The Demand claimed that NeuroRx, failed to satisfy its obligation to pay GEM a commitment fee in the amount of HK$15,000,000 (approximately US$1,919,565 at current exchange rates) pursuant to the GEM Agreement. ​ On July 17, 2023, NeuroRx and GEM entered into a settlement and release agreement (the “Settlement Agreement”) pursuant to which the parties agreed to dismiss the arbitration proceeding with prejudice. Pursuant to the Settlement Agreement on August 31, 2023, the Company issued 675,676 shares of Common Stock to GEM in full satisfaction of the Settlement Agreement for the approximately $0.3 million which was previously accrued and expensed as “Settlement expense.” The shares are registered under a prospectus supplement to the Company’s registration statement on Form S-3 and are subject to a restriction that they cannot be sold or traded for a period of six months from the effective date of the Settlement Agreement. ​ Other Legal Actions: ​ We are currently involved in and may from time to time become involved in various legal actions incidental to our business. As of the date of this report, we are not involved in any legal proceedings that we believe could have a material adverse effect on our financial position or results of operations. However, the outcome of any current or future legal proceeding is inherently difficult to predict and any dispute resolved unfavorably could have a material adverse effect on our business, financial position, and operating results. ​

Equity

Equity	9 Months Ended
	Sep. 30, 2023
Equity
Equity	9. Equity Common Stock Pursuant to the terms of the Company’s Second Amended and Restated Certificate of Incorporation, the Company has authorized 500,000,000 shares of common stock with a par value of $0.001 . As discussed above in Note 2, on March 8, 2023, NRx Pharmaceuticals entered into a securities purchase agreement with the March Investors, providing for the issuance and sale of 3,866,666 shares of Common Stock and the March Investor Warrants to purchase up to 3,866,666 shares of Common Stock in a registered direct offering priced at-the-market under Nasdaq rules for a purchase price of $0.75 per share. The March Investors agreed not to transfer the Common Stock for six months following the date of issuance. The aggregate gross proceeds to the Company from the March Offering were approximately $2.9 million. The securities were issued pursuant to the Company’s registration statement on Form S-3 filed with the SEC on June 9, 2022 (File No. 333-265492) which became effective on June 21, 2022. ​ On February 8, 2023, the Company entered into a letter agreement with H.C. Wainwright & Co., LLC. Although they did not act as the placement agent with respect to the March Offering, H.C. Wainwright & Co., LLC was paid a cash fee equal to 3.0% of the amount raised, or approximately $0.1 million, pursuant to the letter agreement. ​ On June 6, 2023, the Company entered into a securities purchase agreement with the June Investors, providing for the issuance and sale of 9,670,002 shares of the Company’s Common Stock and the June Investor Warrants to purchase up to 9,670,002 shares of Common Stock. The Common Stock was issued in a registered direct offering for a purchase price of $0.65 per share and the June Investor Warrants were offered pursuant to a private placement under Section 4(a)(2) of the Securities Act. The aggregate net cash proceeds to the Company from the June Offering were approximately $5.7 million. The Company intends to use the net proceeds from the June Offering for working capital and general corporate purposes. ​ H.C. Wainwright & Co. LLC acted as the exclusive placement agent (the “Placement Agent”) for the June 2023 Offering. The Placement Agent was paid a cash fee equal to 6.5% of the gross proceeds received by the Company from the sale of the securities at the closing of the June Offering or approximately $0.6 million. The Company intends to use the net proceeds from such offering for working capital and general corporate purposes. ​ The Company sold 7,824,727 shares of common stock during the nine months ended September 30, 2022 and received gross proceeds of $ 23.0 million. Preferred Stock ​ Pursuant to the terms of the Company’s Second Amended and Restated Certificate of Incorporation, the Company has authorized   shares of preferred stock with a par value of $ . ​ Series A Convertible Preferred Stock ​ On August 30, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (“Series A Preferred Stock”) with the Delaware Secretary of State (the “Certificate of Designation”) authorizing up to 12,000,000 shares of Series A Preferred Stock. During the three months ended September 30, 2023, the Company sold and issued 3.0 million shares of Series A Preferred Stock. Each share of Series A Preferred Stock was sold with one warrant (a “Unit") for an aggregate cash purchase price of $1,200,000 ​ Dividend Rights The holders of Series A Preferred Stock are not be entitled to receive any dividends in respect to the Series A Preferred Stock. Voting Rights The holders of Series A Preferred Stock have no voting rights other than for an affirmative vote in order for the Company to (a) disproportionally alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that disproportionally adversely affects any rights of the Holders, (c) increase or decrease the number of authorized shares of Series A Preferred Stock or (d) enter into any agreement with respect to any of the foregoing. Conversion Rights ​ The holders of the Series A Preferred Stock have the right to convert their shares to common stock at any time after the six (6) month anniversary from issuance unless the closing share price of the Company’s Common Stock equals or exceeds $1.20 per share on any trading day of Common Stock equal to the number of shares of Series A Preferred Stock being converted. Notwithstanding the foregoing, no share of Series A Preferred Stock shall be convertible during the six (6) month period following the issuance date; provided, however, if the Common Stock trades at or above $1.20 per share (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events), as reported on Bloomberg, L.P. on any trading day, holder may convert the Series A Preferred Stock prior to the six (6) month anniversary of the issuance date. No fractional shares will be issued upon conversion. Conversion is subject to certain limitations, including the holder not owning more than 4.9% of the outstanding shares of Common Stock. Liquidation Rights Upon any liquidation, dissolution or winding up of the Company (a “Liquidation”), whether voluntary or involuntary, each holder of Series A Preferred Stock shall be entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive if such shares had been converted to Common Stock immediately prior to such Liquidation, subject to certain rights and limitations. Common Stock Warrants ​ Substitute Warrants In connection with the Merger, each warrant to purchase shares of common stock of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) was assumed by BRPA and converted into a warrant, based on the Exchange Ratio (of 3.16), that will continue to be governed by substantially the same terms and conditions, including vesting, as were applicable to the former warrant (the “Substitute Warrants”). As these Substitute Warrants meet the definition of a derivative as contemplated in ASC 815, the Substitute Warrants were recorded as derivative liabilities on the balance sheet and measured at fair value at inception (on the date of the Merger) and at each reporting date in accordance with ASC 820, Fair Value Measurement The Company recognized a gain and loss on the change in fair value of the Substitute Warrants for the three months ended September 30, 2023 and 2022 of less than $0.1 million and less than $0.1 million, respectively. The Company recognized a gain on the change in fair value of the Substitute Warrants for the nine months ended September 30, 2023 and 2022 of less than $0.1 million and $0.1 million, respectively. Refer to Note 11 for further discussion of fair value measurement of the warrant liabilities. Assumed Public Warrants Prior to the Merger, the Company had 3,450,000 Public Warrants outstanding (the “Public Warrants”). Each Public Warrant entitles the holder to purchase one share of Common Stock at an exercise price of $11.50 per share. The Public Warrants became exercisable at the Effective Time of the Merger and expire five years after the Effective Time or earlier upon their redemption or liquidation of the Company. During the three and nine months ended September 30, 2023 and 2022 no Public Warrants were exercised. Assumed Private Placement Warrants Prior to the Merger, the Company had outstanding 136,250 Private Placement Warrants (the “Private Placement Warrants”). The Private Placement Warrants are not indexed to the Company’s common shares in the manner contemplated by ASC 815-40-15 because the holder of the instrument is not an input into the pricing of a fixed-for-fixed option on equity shares. The Company classifies the Private Placement Warrants as derivative liabilities in its Unaudited Condensed Consolidated Balance Sheet as of September 30, 2023. The Company measures the fair value of the Private Placement Warrants at the end of each reporting period and recognizes changes in the fair value from the prior period in the Company’s statements of operations for the current period. The Company recognized a gain on the change in fair value of the Private Placement Warrants for the three months ended September 30, 2023 and 2022 of less than $0.1 million and less than $0.1 million, respectively. The Company recognized a gain on the change in fair value of the Private Placement Warrants for the nine months ended September 30, 2023 and 2022 of less than $0.1 million and $0.2 million, respectively. Refer to Note 11 for discussion of the fair value measurement of the Company’s warrant liabilities. Investor Warrants ​ As discussed above, on March 8, 2023, in conjunction with the issuance and sale of 3,866,666 shares of the Company’s Common Stock, five The March Investor Warrants have an exercise price of $0.75 per share, are initially exercisable beginning six months following the March Initial Exercise Date and will expire five and a half years from the March Initial Exercise Date. The Company issued warrants to the Placement Agent with an exercise price of $0.81 (the “June Placement Agent Warrants”). As these June Placement Agent Warrants were issued for services provided in facilitating the June Offering, the Company recorded the fair value of such June Placement Agent Warrants of approximately $0.1 million as a cost of capital on the issuance date. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $0.53, exercise price of $0.81, term of five ​ In connection with the June Offering, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with certain investors to amend certain existing warrants to purchase up to 9,622,778 shares of Common Stock that were previously issued in August 2021 and February 2022 to such investors, with an exercise price of $3.07 and $12.00 per share, respectively (the “Amended Warrants”) as follows: (i) lower the exercise price of the Amended Warrants to $0.6525 per share, and (ii) provide that the Amended Warrants, as amended, will not be exercisable until six months following the closing date of the June Offering, and (iii) extend the original expiration date of the Amended Warrants so that they will terminate five ​ The Company recorded the incremental change in fair value of such Amended Warrants of $1.7 million as a cost of capital to issue the June Investor Warrants. The measurement of fair value for the Amended Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $0.53, exercise price of $0.65, term of five ​ As discussed above, On August 28, 2023, in conjunction with the issuance and sale of 3,000,000 shares of the Company’s Series A Convertible Preferred Stock, the Company issued 3,000,000 August Investor Warrants The measurement of fair value of the August Investor Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $0.30 , exercise price of $0.40 , term of five years , volatility of 175.1% , risk-free rate of 4.38% , and expected dividend rate of 0% ). The grant date fair value of these August Investor Warrants was estimated to be $0.8 million on August 28, 2023 and is reflected within additional paid-in capital. ​ The following table provides the activity for all warrants for the respective periods. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ Weighted ​ Aggregate ​ ​ ​ Remaining ​ Average ​ Intrinsic Value ​ Total Warrants ​ Term ​ Exercise Price ​ (in thousands) Outstanding as of December 31, 2022 16,484,923 ​ 3.59 ​ $ 6.49 ​ ​ — Issued 3,866,666 ​ 4.69 ​ ​ 0.75 ​ ​ — Outstanding as of March 31, 2023 20,351,589 ​ 3.65 ​ ​ 5.40 ​ ​ — Issued 9,670,002 ​ 4.94 ​ ​ 0.65 ​ ​ — Outstanding as of June 30, 2023 30,021,591 ​ 4.36 ​ $ 2.51 ​ ​ — Issued 3,000,000 ​ 4.92 ​ ​ 0.40 ​ ​ — Outstanding as of September 30, 2023 33,021,591 ​ 4.28 ​ $ 2.32 ​ $ — ​

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2023
Stock-Based Compensation
Stock-Based Compensation	10. Stock-Based Compensation 2016 Omnibus Incentive Plan Prior to the Merger, NeuroRx maintained its 2016 Omnibus Incentive Plan (the “2016 Plan”), under which NeuroRx granted incentive stock options, restricted stock awards, other stock-based awards, or other cash-based awards to employees, directors, and non-employee consultants. The maximum aggregate shares of common stock that were subject to awards and issuable under the 2016 Plan was 3,472,000. In connection with the Merger, each option of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) was assumed by BRPA and converted into an option to acquire an adjusted number of shares of Common Stock at an adjusted exercise price per share (the “Substitute Options”), based on the Exchange Ratio (of 3.16). Upon the closing of the Merger, the outstanding and unexercised NeuroRx stock options became options to purchase an aggregate 2,895,423 shares of the Company’s Common Stock at an average exercise price of $5.10 per share. 2021 Omnibus Incentive Plan As of September 30, 2023, 6,713,608 shares of Common Stock are authorized for issuance pursuant to awards under the Company’s 2021 Omnibus Incentive Plan (the “2021 Plan”). As of January 1, 2023, 664,430 shares were added to the 2021 Plan under an evergreen feature that automatically increases the reserve with additional shares of Common Stock for future issuance under the Incentive Plan each calendar year, beginning January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (A) 1% of the shares of Common Stock outstanding on the final day of the immediately preceding calendar year or (B) a smaller number of shares determined by the Board. Option Awards The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is a public company and has limited company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the limited company-specific historical volatility and implied volatility as well as historical volatility of a publicly traded set of peer companies. The expected term of the Company’s stock options for employees has been determined utilizing the “simplified” method for awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. Additionally, certain options granted contain terms that require all unvested options to immediately vest a) upon the approval of a New Drug Application (NDA) by the FDA for NRX-101, or b) immediately preceding a change in control of the Company, whichever occurs first. The grant date fair value of employee and non-employee stock option awards is determined using the Black Scholes option-pricing model. The Company did not grant any stock options during the three or nine months ended September 30, 2023. ​ The following assumptions were used for the year ended December 31, 2022: ​ ​ ​ ​ ​ ​ December 31, 2022 ​ ​ ​ ​ Exercise price ​ $0.51-$3.10 Risk-free rate of interest 1.8%-4.36% Expected term (years) 5.3-6.5 Expected stock price volatility 94.9%-147.8% Dividend yield — ​ The following table summarizes the Company’s employee and non-employee stock option activity under the Plan for the following periods: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of shares ​ Weighted average exercise price ​ Weighted average remaining contractual life (in years) ​ Aggregate intrinsic value (in thousands) Outstanding as of December 31, 2022 ​ 2,548,849 ​ $ 3.32 ​ 8.4 ​ $ 618 Outstanding as of September 30, 2023 ​ 2,548,849 ​ $ 3.32 ​ 7.6 ​ $ 10 Options vested and exercisable as of September 30, 2023 ​ 2,022,085 ​ $ 3.68 ​ 7.3 ​ $ 10 ​ The weighted average grant date fair value per share for employee stock and non-employee option grants during the three and nine months ended September 30, 2022 was $0.64 and $1.55, respectively. At September 30, 2023, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted, was $0.8 million, which the Company expects to recognize over a weighted-average period of approximately 0.6 years. The following table summarizes the Company’s recognition of stock-based compensation for the following periods (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended September 30, ​ Nine months ended September 30, ​ 2023 2022 2023 2022 Stock-based compensation expense ​ ​ ​ ​ General and administrative ​ $ 261 ​ $ 506 ​ $ 1,295 ​ $ 2,390 Research and development ​ 90 ​ 35 ​ 295 ​ 472 Total stock-based compensation expense ​ $ 351 ​ $ 541 ​ $ 1,590 ​ $ 2,862 ​ Restricted Stock Awards The following table presents the Company’s Restricted Stock Activity: ​ ​ ​ ​ ​ ​ ​ ​ Awards ​ Weighted Average Grant Date Fair Value Balance as of December 31, 2022 ​ 1,000,000 ​ $ 0.57 Vested ​ 333,333 ​ - Balance as of September 30, 2023 ​ 666,667 ​ $ 0.57 ​ As of September 30, 2023, total unrecognized compensation expense related to RSAs granted was approximately $0.3 million, which is expected to be recognized over a weighted-average period of approximately 1.8 years. Stock-based compensation expense related to RSAs was approximately less than $0.1 million and $0.2 million during the three and nine months ended September 30, 2023.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Measurements
Fair Value Measurements	11. Fair Value Measurements Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the three and nine months ended September 30, 2023 and year ended December 31, 2022. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of warrants issued for services are estimated based on the Black-Scholes model during the three and nine months ended September 30, 2023 and year ended December 31, 2022. The fair value of the Note was estimated utilizing a Monte Carlo simulation during the three and nine months ended September 30, 2023 and the year ended December 31, 2022. Fair Value on a Recurring Basis The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the money market account represents a Level 1 measurement. The estimated fair value of the warrant liabilities and earnout cash contingent consideration represent Level 3 measurements. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at September 30, 2023 and year ended December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30 ​ December 31 Description Level 2023 ​ 2022 Assets: ​ ​ ​ (Unaudited) ​ ​ ​ Money Market Account ​ 1 ​ $ 7,034 ​ $ 15,249 ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ Warrant liabilities (Note 11) ​ 3 ​ $ 10 ​ $ 37 Convertible note payable (Note 7) 3 ​ $ 10,069 ​ $ 10,525 ​ Convertible Note Payable The significant inputs used in the Monte Carlo simulation to measure the convertible note liability that is categorized within Level 3 of the fair value hierarchy are as follows: ​ ​ ​ ​ ​ ​ September 30, 2023 Stock price on valuation date ​ $ 0.26 Time to expiration ​ ​ 0.59 Note market interest rate ​ ​ 8.4% Equity volatility ​ 90.0% Volume volatility ​ ​ 365.0% Risk-free rate ​ 5.52% Probability of default ​ 3.2% ​ The following table sets forth a summary of the changes in the fair value of the Note categorized within Level 3 of the fair value hierarchy (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ December 31, 2022 ​ ​ (Unaudited) ​ ​ ​ Par value of the Note ​ $ 11,020 ​ $ 11,020 Debt discount ​ ​ (497) ​ ​ (1,000) Repayment of principal and interest ​ ​ (3,270) ​ ​ — Carrying value of the Note before current period change in fair value ​ ​ 7,253 ​ ​ 10,020 Fair value adjustment through earnings ​ ​ 2,794 ​ ​ 505 Fair value adjustment through accumulated other comprehensive income ​ ​ 22 ​ ​ — Total carrying value of Note ​ $ 10,069 ​ $ 10,525 ​ ​ ​ ​ ​ ​ ​ Convertible note payable - current portion ​ $ 10,069 ​ $ 7,703 Convertible note payable, net of current portion ​ $ — ​ $ 2,822 ​ Warrant Liabilities The Company utilizes a Black-Scholes model approach to value the Private Placement Warrants and Substitute Warrants at each reporting period, with changes in fair value recognized in the statement of operations. The estimated fair value of the warrant liabilities is determined using Level 3 inputs. Inherent in a Black Scholes options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock based on historical and peer company volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The significant inputs used in the Black-Scholes model to measure the warrant liabilities that are categorized within Level 3 of the fair value hierarchy are as follows: ​ ​ ​ ​ ​ September 30, 2023 Stock price on valuation date ​ $ 0.26 - 0.66 Exercise price per share ​ $ 3.48 - 11.50 Expected life ​ 0.02 - 3.15 Volatility ​ 55.0 - 175.1% Risk-free rate ​ 3.79 - 5.40% Dividend yield ​ 0.00% Fair value of warrants ​ $ 0.00 - 79.34 ​ A reconciliation of warrant liabilities is included below (in thousands): ​ ​ ​ ​ ​ September 30, 2023 Balance as of December 31, 2022 ​ $ 37 Gain upon re-measurement ​ ​ (12) Balance as of March 31, 2023 ​ ​ 25 Gain upon re-measurement ​ ​ 11 Balance as of June 30, 2023 ​ ​ 36 Gain upon re-measurement ​ ​ (26) Balance as of September 30, 2023 ​ $ 10 ​

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Taxes
Income Taxes	12. Income Taxes The Company recorded no provision or benefit for income tax expense for the nine months ended September 30, 2023 and 2022, respectively. For all periods presented, the pretax losses incurred by the Company received no corresponding tax benefit because the Company concluded that it is more likely than not that the Company will be unable to realize the value of any resulting deferred tax assets. The Company will continue to assess its position in future periods to determine if it is appropriate to reduce a portion of its valuation allowance in the future. The Company has no open tax audits with any taxing authority as of September 30, 2023.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions
Related Party Transactions	13. Related Party Transactions Glytech Agreement The Company licenses patents that are owned by Glytech, LLC (“Glytech”), pursuant to a license agreement (the “Glytech Agreement”). Glytech is owned by a co-founder and former director of the Company. The Glytech Agreement requires that the Company pay Glytech for ongoing scientific support and also reimburse Glytech for expenses of obtaining and maintaining patents that are licensed to NRx Pharmaceuticals. During the three months ended September 30, 2023 and 2022, the Company paid Glytech $0.1 million and $0.1 million, respectively, for continuing technology support services and reimbursed expenses. During the nine months ended September 30, 2023 and 2022, the Company paid Glytech $0.2 million and $0.2 million, respectively, for continuing technology support services and reimbursed expenses. These support services are ongoing. The Fourth Amendment to the Glytech Agreement, effective as of December 31, 2020, includes an equity value-triggered transfer of Excluded Technology from Glytech to NRx Pharmaceuticals. The Excluded Technology is defined in the Glytech Agreement as any technology, and any know-how related thereto, covered in the licensed patents that do not recite either D-cycloserine or lurasidone individually or jointly. This definition would cover pharmaceutical formulations, including some that NRx Pharmaceuticals considers “pipeline” or “future product” opportunities, that contain a combination of pharmaceutical components different from those contained in NRX-100 and NRX-101. On November 6, 2022 the Glytech Agreement was amended whereby Glytech agreed to transfer and assign the remainder of the Licensed Technology and the Excluded Technology to NRx Pharmaceuticals for no additional consideration at any time upon receipt of written notice from the Company if, on or prior to January 31, 2023, (i) the value of the Glytech equity holdings in NRx Pharmaceuticals (the “Glytech Equity”) has an aggregate liquidity value of at least $50 million for twenty (20) consecutive trading days immediately preceding any given date and (ii) there are no legal or contractual restrictions on selling all of the securities represented by the Glytech Equity then applicable to Glytech (or reasonably foreseeable to be applicable to Glytech within the following twenty trading days). The Glytech Agreement was amended to extend the period to meet these conditions until August 6, 2023 and the parties are currently negotiating an extension to meet these conditions. Consulting Agreement with Dr. Jonathan Javitt The Chief Scientist of the Company, Dr. Jonathan Javitt, is a major shareholder in the Company and a member of the Board of Directors. Therefore, his services are deemed to be a related party transaction. He served the Company on a full-time basis as CEO under an employment agreement with the Company until March 8, 2022 and currently serves under a Consulting Agreement with the Company as Chief Scientist thereafter and received compensation of $0.2 million and $0.2 million during the three months ended September 30, 2023 and 2022, respectively, and $0.7 million and $0.7 million during the nine months ended September 30, 2023 and 2022, respectively. On March 29, 2023, the Consulting Agreement dated March 8, 2022 (the “Javitt Consulting Agreement”) between the Company and Dr. Jonathan Javitt was amended to extend the term of the Agreement until March 8, 2024 with automatic annual renewals thereafter unless one party or the other provides notice of non-renewal. The amendment also provided for payment at the rate of $0.6 million per year, payable monthly (i.e., less than $0.1 million per month), and a performance-based annual bonus with a minimum target of $0.3 million, at the discretion of the Board and upon satisfactory performance of the services. The annual bonus for 2023, if any, is payable in March 2024, will be pro-rated from the start of the extension period and is subject to Dr. Javitt’s continued engagement by the Company. The amendment also provides, subject to the approval of the Board of Directors, for a grant of 500,000 shares of restricted stock of the Company under the Company’s 2021 Omnibus Incentive Plan. The restrictions are performance based, and half of the restricted shares (250,000) shall have the restrictions removed on the New Drug Application Date (as defined below) and the remaining half (250,000) will have the restrictions removed on the New Drug Approval Date (as defined below). As of September 30, 2023, the Board of Directors has not approved the grant of restricted stock. The term “New Drug Application Date” means the date upon which the Food and Drug Administration (“FDA”) files the Company’s new drug application for the Antidepressant Drug Regimen (as defined below) for review. The term “New Drug Approval Date” means date upon which the FDA has both approved the Company’s Antidepressant Drug Regimen and listed the Company’s Antidepressant Drug Regimen in the FDA’s “Orange Book”. The term “Antidepressant Drug Regimen” means NRX-101, a proprietary fixed-dose combination capsule of d-cycloserine and Lurasidone, administered for sequential weeks of daily oral treatment following patient stabilization using a single infusion of NRX-100 (ketamine) or another standard of care therapy. Consulting Agreement with Zachary Javitt ​ Zachary Javitt is the son of Dr. Jonathan Javitt. Zachary Javitt provides services related to website, IT, and marketing support under the supervision of the Company’s CEO who is responsible for assuring that the services are provided on financial terms that are at market. The Company paid this family member a total of $0.1 million and less than $0.1 million during the three months ended September 30, 2023 and 2022, respectively. The Company paid this family member a total of $0.1 million and $0.1 million during the nine months ended September 30, 2023 and 2022, respectively. These services are ongoing. Agreements with PillTracker The Company paid PillTracker for digital health product development required to track the use of Aviptadil in clinical trials. Zachary Javitt and Dr. Jonathan Javitt are the chief executive officer and board chairman, respectively, of PillTracker. PillTracker agreements and transactions are submitted to the General Counsel of the Company and the Chair of the Audit Committee for approval in accordance with the terms of the Company’s Related Person Transactions Policy. The Master Service Agreement dated April 1, 2020, and all work orders thereunder, have been suspended by mutual agreement pending the Company’s re-evaluation of its respiratory franchise. NRx Pharmaceuticals paid PillTracker $0.2 million during the nine months ended September 30, 2022. No Pilltracker-related expenses have been recognized or are anticipated in 2023. Included in accounts payable were less than $0.1 million and less than $0.1 million due to the above related parties as of September 30, 2023 and December 31, 2022, respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events
Subsequent Events	14. Subsequent Events ​ Compliance with Nasdaq Listing Requirements ​ On October 17, 2023, the Company received formal notice from the Listing Qualifications Staff (the “Staff”) indicating that, based upon the Company’s non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”), the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel(the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the issuance of a decision by the Panel and the expiration of any extension that the Panel may grant to the Company following the hearing. The Company is diligently working to evidence compliance with the Rule; however, there can be no assurance that the Panel will determine to continue the Company’s listing or that the Company will be able to evidence compliance with the applicable listing criteria within the time period of any extension that may be granted by the Panel. The Company has now been granted a hearing date of January 4, 2024 at which the Company will present its plan for achieving Nasdaq continued listing requirements. The Nasdaq has invited the Company to submit a short-form written response detailing that compliance plan, which at Nasdaq’s election may substitute for the January 4 hearing. The Company has submitted this short form plan to the Nasdaq. ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the balance sheet, statements of operations and cash flows for the interim periods presented. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.
Use of Estimates	Use of Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the convertible note payable, earnout cash liability, stock options, warrants, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Certain Risks and Uncertainties	Certain Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. (Refer to Note 11)
Concentration of Credit Risk and Off-Balance Sheet Risk	Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions may, from time to time, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy.
Revenue Recognition	Revenue Recognition Arrangements may include licenses to intellectual property, research services and participation on joint research committees. The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of research, the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. ​ The Company enters into contractual arrangements that may include licenses to intellectual property and research and development services. When such contractual arrangements are determined to be accounted for in accordance with ASC 606, Revenue from Contracts with Customers ​ The License Agreement with Alvogen as further discussed in Note 6 below is accounted for in accordance with ASC 606. In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following five steps: ​ i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations within the contract; and v. recognize revenue when (or as) the entity satisfies a performance obligation. ​ The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. ​ At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements typically consist of a license to intellectual property and research services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. ​ The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. ​ The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. ​ The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. ​ The Company’s revenue arrangements include the following: ​ Milestone Payments: At the inception of an agreement that includes milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. ​ Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). ​ Research Services: The Company is incurring research costs in association with the Alvogen agreement. After the First Milestone Payment (as defined in Note 6 below), the Company will be reimbursed for certain costs incurred related to reasonable and documented out-of-pocket costs for clinical and non-clinical development activities. The Company will recognize revenue for the reimbursed costs when the First Milestone Payment contingencies have been achieved and the Company has an enforceable claim to the reimbursed costs. ​ See Note 6, “Alvogen Licensing Agreement”, for further information on the application of ASC 606 to the License Agreement.
Research and Development Costs	Research and Development Costs ​ The Company’s research and development expenses consist primarily of costs associated with the Company’s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.
Convertible Note Payable	Convertible Note Payable ​ As permitted under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 825, Financial Instruments (“ASC 825”), the Company elects to account for its convertible promissory note, which meets the required criteria, at fair value at inception and at each subsequent reporting date. Subsequent changes in fair value are recorded as a component of non-operating loss in the consolidated statements of operations. The portion of total changes in fair value of the convertible note attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income in the accompanying Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. As a result of electing the fair value option, direct costs and fees related to the convertible promissory notes are expensed as incurred. ​ The Company estimates the fair value of the convertible note payable using a Monte Carlo simulation model, which uses as inputs the fair value of our common stock and estimates for the equity volatility and volume volatility of our common stock, the time to expiration of the convertible note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, we estimate our expected future volatility based on the actual volatility of our common stock and historical volatility of our common stock utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning six months from the issuance date. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default is estimated using Bloomberg's Default Risk function which uses our financial information to calculate a default risk specific to the Company.
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock- based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company’s common stock on the date of issuance. All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual’s role at the Company.
Warrants	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The fair value of the Private Placement Warrants (as defined below) was estimated using a Black Scholes valuation approach and the fair value of the Substitute Warrants (as defined below) was estimated using a modified Black Scholes valuation approach which applies a probability factor based on the probabilities of achieving earnout cash milestone and/or earnout shares milestone at each reporting period (see Notes 9 and 11).
Modification of warrants	Modification of Warrants A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which may result in a reduction of additional paid-in capital, recognition of costs for services rendered, or recognized as a deemed dividend.
Preferred Stock	Preferred Stock ​ In accordance with ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging – Contracts in an Entity’s Own Equity
Income Taxes	Income Taxes Income Taxes
Loss Per Share	Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, common stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss. The following outstanding shares of common stock equivalents were excluded from the computation of the diluted net loss per share attributable to common stock for the periods in which a net loss is presented because their effect would have been anti-dilutive. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2023 2022 2023 2022 Stock options ​ 2,548,849 2,654,579 2,548,849 2,654,579 Restricted stock awards ​ 666,667 ​ 1,000,000 ​ 666,667 ​ 1,000,000 Convertible preferred stock ​ 3,000,000 ​ — ​ 3,000,000 ​ — Common stock warrants ​ 33,021,591 17,521,753 33,021,591 17,521,753 Earnout Shares ​ — ​ 22,209,280 ​ — ​ 22,209,280 Earnout Shares from exercised Substitute Options and Substitute Warrants ​ — ​ 1,229,925 ​ — ​ 1,229,925
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. For the nine months ended September 30, 2023, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, that management believes materially affect the Company’s present or future results of operations, overall financial condition, liquidity or disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2023
Summary of Significant Accounting Policies
Schedule of Outstanding Shares of Common Stock Equivalents Excluded From Diluted Net Loss Per Share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ 2023 2022 2023 2022 Stock options ​ 2,548,849 2,654,579 2,548,849 2,654,579 Restricted stock awards ​ 666,667 ​ 1,000,000 ​ 666,667 ​ 1,000,000 Convertible preferred stock ​ 3,000,000 ​ — ​ 3,000,000 ​ — Common stock warrants ​ 33,021,591 17,521,753 33,021,591 17,521,753 Earnout Shares ​ — ​ 22,209,280 ​ — ​ 22,209,280 Earnout Shares from exercised Substitute Options and Substitute Warrants ​ — ​ 1,229,925 ​ — ​ 1,229,925

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Prepaid Expenses and Other Current Assets
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets consisted of the following at the dates indicated (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ December 31, 2022 ​ ​ (Unaudited) ​ ​ ​ Prepaid expenses and other current assets: ​ ​ Prepaid clinical development expenses ​ $ 1,999 ​ $ 1,966 Prepaid insurance ​ ​ 1,517 ​ ​ 3,167 Other prepaid expenses ​ ​ 665 ​ ​ 331 Prepaid legal expenses ​ — ​ 270 Other current receivables ​ ​ 6 ​ ​ 7 Total prepaid expenses and other current assets ​ $ 4,187 ​ $ 5,741 ​

Accrued and Other Current Lia_2

Accrued and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Accrued and Other Current Liabilities
Schedule of accrued and other current liabilities	Accrued and other current liabilities consisted of the following at the dates indicated (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ December 31, 2022 ​ ​ ​ (Unaudited) ​ ​ ​ Accrued and other current liabilities: ​ ​ ​ ​ ​ ​ Other accrued expenses ​ $ 173 ​ $ 2,616 Accrued employee expenses ​ 739 ​ 923 Accrued research and development expenses ​ ​ 1,045 ​ ​ 974 Professional services ​ ​ 2,771 ​ ​ 342 Total accrued and other current liabilities ​ $ 4,728 ​ $ 4,855 ​

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt.
Summary of Convertible note payable	The following table presents the Note as of September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ December 31, 2022 ​ ​ (Unaudited) ​ ​ ​ Par value of the Note ​ $ 11,020 ​ $ 11,020 Debt discount ​ ​ (497) ​ ​ (1,000) Repayment of principal and interest ​ ​ (3,270) ​ ​ — Carrying value of the Note before current period change in fair value ​ ​ 7,253 ​ ​ 10,020 Fair value adjustment through earnings ​ ​ 2,794 ​ ​ 505 Fair value adjustment through accumulated other comprehensive income ​ ​ 22 ​ ​ — Total carrying value of Note ​ $ 10,069 ​ $ 10,525 ​ ​ ​ ​ ​ ​ ​ Convertible note payable - current portion ​ $ 10,069 ​ $ 7,703 Convertible note payable, net of current portion ​ $ — ​ $ 2,822 ​

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Equity
Summary of activity for warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ Weighted ​ Aggregate ​ ​ ​ Remaining ​ Average ​ Intrinsic Value ​ Total Warrants ​ Term ​ Exercise Price ​ (in thousands) Outstanding as of December 31, 2022 16,484,923 ​ 3.59 ​ $ 6.49 ​ ​ — Issued 3,866,666 ​ 4.69 ​ ​ 0.75 ​ ​ — Outstanding as of March 31, 2023 20,351,589 ​ 3.65 ​ ​ 5.40 ​ ​ — Issued 9,670,002 ​ 4.94 ​ ​ 0.65 ​ ​ — Outstanding as of June 30, 2023 30,021,591 ​ 4.36 ​ $ 2.51 ​ ​ — Issued 3,000,000 ​ 4.92 ​ ​ 0.40 ​ ​ — Outstanding as of September 30, 2023 33,021,591 ​ 4.28 ​ $ 2.32 ​ $ — ​

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Stock-Based Compensation
Summary of fair value determined using the Black-Scholes option-pricing model	​ ​ ​ ​ ​ ​ December 31, 2022 ​ ​ ​ ​ Exercise price ​ $0.51-$3.10 Risk-free rate of interest 1.8%-4.36% Expected term (years) 5.3-6.5 Expected stock price volatility 94.9%-147.8% Dividend yield —
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of shares ​ Weighted average exercise price ​ Weighted average remaining contractual life (in years) ​ Aggregate intrinsic value (in thousands) Outstanding as of December 31, 2022 ​ 2,548,849 ​ $ 3.32 ​ 8.4 ​ $ 618 Outstanding as of September 30, 2023 ​ 2,548,849 ​ $ 3.32 ​ 7.6 ​ $ 10 Options vested and exercisable as of September 30, 2023 ​ 2,022,085 ​ $ 3.68 ​ 7.3 ​ $ 10
Summary of recognition of stock-based compensation	The following table summarizes the Company’s recognition of stock-based compensation for the following periods (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended September 30, ​ Nine months ended September 30, ​ 2023 2022 2023 2022 Stock-based compensation expense ​ ​ ​ ​ General and administrative ​ $ 261 ​ $ 506 ​ $ 1,295 ​ $ 2,390 Research and development ​ 90 ​ 35 ​ 295 ​ 472 Total stock-based compensation expense ​ $ 351 ​ $ 541 ​ $ 1,590 ​ $ 2,862
Schedule of restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ Awards ​ Weighted Average Grant Date Fair Value Balance as of December 31, 2022 ​ 1,000,000 ​ $ 0.57 Vested ​ 333,333 ​ - Balance as of September 30, 2023 ​ 666,667 ​ $ 0.57

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Summary of fair value hierarchy	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30 ​ December 31 Description Level 2023 ​ 2022 Assets: ​ ​ ​ (Unaudited) ​ ​ ​ Money Market Account ​ 1 ​ $ 7,034 ​ $ 15,249 ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ Warrant liabilities (Note 11) ​ 3 ​ $ 10 ​ $ 37 Convertible note payable (Note 7) 3 ​ $ 10,069 ​ $ 10,525
Schedule of measure the convertible note liability	​ ​ ​ ​ ​ ​ September 30, 2023 Stock price on valuation date ​ $ 0.26 Time to expiration ​ ​ 0.59 Note market interest rate ​ ​ 8.4% Equity volatility ​ 90.0% Volume volatility ​ ​ 365.0% Risk-free rate ​ 5.52% Probability of default ​ 3.2%
Summary of Convertible note payable	The following table presents the Note as of September 30, 2023 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ December 31, 2022 ​ ​ (Unaudited) ​ ​ ​ Par value of the Note ​ $ 11,020 ​ $ 11,020 Debt discount ​ ​ (497) ​ ​ (1,000) Repayment of principal and interest ​ ​ (3,270) ​ ​ — Carrying value of the Note before current period change in fair value ​ ​ 7,253 ​ ​ 10,020 Fair value adjustment through earnings ​ ​ 2,794 ​ ​ 505 Fair value adjustment through accumulated other comprehensive income ​ ​ 22 ​ ​ — Total carrying value of Note ​ $ 10,069 ​ $ 10,525 ​ ​ ​ ​ ​ ​ ​ Convertible note payable - current portion ​ $ 10,069 ​ $ 7,703 Convertible note payable, net of current portion ​ $ — ​ $ 2,822 ​
Schedule of significant unobservable inputs	The significant inputs used in the Black-Scholes model to measure the warrant liabilities that are categorized within Level 3 of the fair value hierarchy are as follows: ​ ​ ​ ​ ​ September 30, 2023 Stock price on valuation date ​ $ 0.26 - 0.66 Exercise price per share ​ $ 3.48 - 11.50 Expected life ​ 0.02 - 3.15 Volatility ​ 55.0 - 175.1% Risk-free rate ​ 3.79 - 5.40% Dividend yield ​ 0.00% Fair value of warrants ​ $ 0.00 - 79.34
Common stock warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Schedule of reconciliation of liabilities	A reconciliation of warrant liabilities is included below (in thousands): ​ ​ ​ ​ ​ September 30, 2023 Balance as of December 31, 2022 ​ $ 37 Gain upon re-measurement ​ ​ (12) Balance as of March 31, 2023 ​ ​ 25 Gain upon re-measurement ​ ​ 11 Balance as of June 30, 2023 ​ ​ 36 Gain upon re-measurement ​ ​ (26) Balance as of September 30, 2023 ​ $ 10 ​
Convertible notes payable | Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Summary of Convertible note payable	The following table sets forth a summary of the changes in the fair value of the Note categorized within Level 3 of the fair value hierarchy (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ December 31, 2022 ​ ​ (Unaudited) ​ ​ ​ Par value of the Note ​ $ 11,020 ​ $ 11,020 Debt discount ​ ​ (497) ​ ​ (1,000) Repayment of principal and interest ​ ​ (3,270) ​ ​ — Carrying value of the Note before current period change in fair value ​ ​ 7,253 ​ ​ 10,020 Fair value adjustment through earnings ​ ​ 2,794 ​ ​ 505 Fair value adjustment through accumulated other comprehensive income ​ ​ 22 ​ ​ — Total carrying value of Note ​ $ 10,069 ​ $ 10,525 ​ ​ ​ ​ ​ ​ ​ Convertible note payable - current portion ​ $ 10,069 ​ $ 7,703 Convertible note payable, net of current portion ​ $ — ​ $ 2,822

Organization (Details)

Organization (Details)	1 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended
	Apr. 30, 2023 state	Sep. 30, 2023 patent	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023 person
Related Party Transaction [Line Items]
Percentage of standard set for veteran rating team and site raters					90%
Percentage of threshold congruence achieved			94%
Threshold number of states covered under the recruitment campaign | state	45
Minimum shelf life of supplies				2 years
Threshold number of patients' data that would be enough demonstrate preliminary safety and efficacy | patent		200
Number of patients in randomized prospective trial | person						200
NRX-101 | License Agreement | Alvogen
Related Party Transaction [Line Items]
Initial term					20 years
Renewal term					2 years
NRX-100
Related Party Transaction [Line Items]
Number Of Participants Reviewed | patent		240
Number of patients in inpatient trial | person						156

Liquidity (Details)

Liquidity (Details)				3 Months Ended	9 Months Ended
	Aug. 28, 2023 USD ($) item $ / shares shares	Jun. 06, 2023 USD ($) $ / shares shares	Mar. 08, 2023 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2022 shares	Jun. 30, 2023 $ / shares	Mar. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares
Debt Instrument [Line Items]
Cash | $				$ 8,900,000	$ 8,900,000
Common stock and warrants issued, net of issuance costs (in shares) | shares						7,824,727
Warrants, exercise price per share				$ 2.32	$ 2.32		$ 2.51	$ 5.40	$ 6.49
Preferred stock, par value				0.001	$ 0.001				0.001
Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs | $					$ 1,171,000
Series A Convertible Preferred Stock
Debt Instrument [Line Items]
Preferred stock, par value				$ 0.001	$ 0.001				$ 0.001
Securities Purchase Agreement
Debt Instrument [Line Items]
Common stock and warrants issued, net of issuance costs (in shares) | shares			3,866,666
Price per unit			$ 0.75
Warrants, exercise price per share			$ 0.75
Warrants expiration term			5 years
Proceeds from issuance of Common stock, net of transaction costs | $			$ 2,900,000
Securities Purchase Agreement June Investors
Debt Instrument [Line Items]
Common stock and warrants issued, net of issuance costs (in shares) | shares		9,670,002
Price per unit		$ 0.65
Warrants, exercise price per share		$ 0.6525
Warrants expiration term		5 years
Proceeds from issuance of Common stock, net of transaction costs | $		$ 5,710,000
Securities Purchase Agreement June Investors | Minimum
Debt Instrument [Line Items]
Warrants and rights exercisable term		6 months
Securities purchase agreement, august investors
Debt Instrument [Line Items]
Number of shares issued | shares	3,000,000
Number of warrants issued with each share | $				1
Securities purchase agreement, august investors | Series A Convertible Preferred Stock
Debt Instrument [Line Items]
Price per unit	$ 0.40
Warrants and rights exercisable term	6 months
Warrants expiration term	5 years
Number of shares issued | shares	3,000,000			3,000,000
Preferred stock, par value	$ 0.001
Number of warrants issued with each share | item	1
Number of shares per warrant | shares	1
Stock price on valuation date	$ 0.40
Warrants exercisable, common stock price threshold , specified trading days	$ 1.20
Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs | $	$ 1,200,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,548,849	2,654,579	2,548,849	2,654,579
Restricted stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	666,667	1,000,000	666,667	1,000,000
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,000,000		3,000,000
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	33,021,591	17,521,753	33,021,591	17,521,753
Earnout Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		22,209,280		22,209,280
Earnout Shares from exercised Substitute Options and Substitute Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		1,229,925		1,229,925

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Prepaid Expenses and Other Current Assets
Prepaid clinical development expenses	$ 1,999	$ 1,966
Prepaid insurance	1,517	3,167
Other prepaid expenses	665	331
Prepaid legal expenses		270
Other current receivables	6	7
Total prepaid expenses and other current assets	$ 4,187	$ 5,741

Accrued and Other Current Lia_3

Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accrued and other current liabilities:
Other accrued expenses	$ 173	$ 2,616
Accrued employee expenses	1,045	974
Accrued research and development expenses	739	923
Professional services	2,771	342
Total accrued and other current liabilities	$ 4,728	$ 4,855

Alvogen Licensing Agreement (De

Alvogen Licensing Agreement (Details) - NRX-101 - License Agreement - Alvogen - USD ($) $ in Millions		6 Months Ended
	Jun. 02, 2023	Jun. 30, 2023
Alvogen Licensing Agreement
Initial term		20 years
Renewal term		2 years
Equity royalty payable period in case of reversion license	30 days
First milestone payment to be received	$ 10
Second milestone payment receivable	5
Maximum bonus milestone payment receivable	$ 330

Debt - Convertible Note (Detail

Debt - Convertible Note (Details)				3 Months Ended	9 Months Ended	12 Months Ended
	Jul. 07, 2023 USD ($)	May 01, 2023 USD ($) D	Nov. 04, 2022 USD ($) D	Sep. 30, 2023 USD ($) item	Sep. 30, 2023 USD ($) item	Dec. 31, 2022 USD ($)	Mar. 30, 2023
Debt discount				$ 497,000	$ 497,000	$ 1,000,000
Fair value adjustment through earnings				$ (359,000)	$ (2,794,000)	(505,000)
Default Trigger Events [Member]
Interest rate percentage				18%	18%
Number of trading days					5
Event of Default | item				0	0
Promissory Note 9% Redeemable [Member]
Interest rate percentage			9%
Debt Instrument, Face Amount			$ 11,000,000
Maturity term			18 months
Original issue discount			$ 1,000,000
Net proceeds from issuance of notes			$ 10,000,000
Amount payable on prepayment of notes as a percentage of the principal, interest, and fees owed			110%
Maximum outstanding balance of the Note that can be redeemed by the holder per month			$ 1,000,000
Percentage of premium payable on amount redeemed if the notes are redeemed in cash			10%
Redemption Conversion Price as a percentage of average lowest daily volume weighted average prices per share of the common stock			85%
Redemption Conversion Price, Number of lowest daily volume weighted average prices per share of the common stock considered | D			2
Redemption Conversion Price, Number of trading days considered | D			10
Minimum percentage of daily dollar trading volume of the common stock considered to trigger redemption of Notes		50%
Number of previous trading days over which the median daily dollar trading volume is considered to trigger redemption of Notes | D		10
Minimum percentage by which the closing trade price exceeds the Nasdaq Minimum Price, considered to trigger redemption of Notes		30%
Number of following trading days over which the closing trade price is considered to trigger redemption of Notes | D		10
Monthly redemption amount		$ 1,000,000
Maximum percentage of Common Stock outstanding							9.99%
Cash interest repayments made				$ 500,000	$ 700,000
Shares of common stock issued as interest repayment				100,000	100,000
Cash principal repayments made				1,700,000	1,800,000
Shares of common stock issued as principal repayment				900,000	900,000
Debt discount						$ 1,000,000
Fair value adjustment through earnings				$ 2,800,000	$ 400,000
Promissory Note 9% Redeemable [Member] | Amendment Two [Member]
Amount agreed to pay in cash to amend the redemption provisions	$ 1,800,000
Maximum monthly redemption amount per month	1,000,000
Minimum Payment	$ 400,000

Debt - Convertible note payable

Debt - Convertible note payable (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Short-term Debt [Line Items]
Par value of the Note	$ 11,020		$ 11,020		$ 11,020
Debt discount	(497)		(497)		(1,000)
Repayment of Principal	(3,270)		(3,270)
Carrying value of the Note before current period change in fair value	7,253		7,253		10,020
Fair value adjustment through earnings	(359)		(2,794)		(505)
Fair value adjustment through accumulated other comprehensive income			22
Total carrying value of Note	10,069		10,069		10,525
Convertible note payable - current portion	10,069		10,069		7,703
Convertible note payable, net of current portion					2,822
Interest repayments	40		40	$ 3
Stock Issued During Period, Value, Conversion of Convertible Securities	782	$ 200	982
Promissory Note 9% Redeemable [Member]
Short-term Debt [Line Items]
Debt discount					$ (1,000)
Fair value adjustment through earnings	$ 2,800		$ 400

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Commitments and Contingencies [Line Items]
Research and development expenses	$ 3,314	$ 4,129	$ 10,837	$ 12,571
Maximum
Commitments and Contingencies [Line Items]
Operating Lease, Expense	$ 100		100
Exclusive License Agreement
Commitments and Contingencies [Line Items]
Research and development expenses			$ 200

Commitments and Contingencies -

Commitments and Contingencies - Sponsored Research Agreement with National Jewish Health (Details) $ in Millions	Feb. 08, 2021 USD ($)
Sponsored Research Agreement [Member]
Related Party Transaction [Line Items]
Research commitments	$ 0.4

Commitments and Contingencies_2

Commitments and Contingencies - Relief Therapeutics Collaboration Agreement (Details) - Relief Therapeutics Collaboration Agreement [Member] - Relief Therapeutics Lawsuit - Relief Therapeutics Holdings, AG $ in Millions	Sep. 18, 2020 USD ($)
Related Party Transaction [Line Items]
Milestone payments receivable	$ 13
Royalty payments receivable	30
Indemnity claims	0.5
Maximum
Related Party Transaction [Line Items]
Representations and Warranties	2
Covenants and Other Agreements	$ 3

Commitments and Contingencies_3

Commitments and Contingencies - GEM Share Subscription Facility Agreement (Details)				3 Months Ended
	Jul. 17, 2023 USD ($) shares	Aug. 12, 2022 USD ($)	Aug. 12, 2022 HKD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022
Related Party Transaction [Line Items]
Common stock issued to settle GEM settlement liability				$ 250,000
GEM Share Subscription Facility Agreement
Related Party Transaction [Line Items]
Share subscription agreement term					3 years
Commitment fee		$ 1,919,565	$ 15,000,000
Common stock issued to settle GEM settlement liability (in shares) | shares	675,676
Common stock issued to settle GEM settlement liability	$ 300,000

Equity - Common and Preferred S

Equity - Common and Preferred Stock (Details)					3 Months Ended	9 Months Ended
	Aug. 28, 2023 item $ / shares shares	Jun. 06, 2023 USD ($) $ / shares shares	Mar. 08, 2023 USD ($) $ / shares shares	Feb. 08, 2023 USD ($)	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2023 $ / shares shares	Sep. 30, 2022 shares	Aug. 30, 2023 shares	Jun. 30, 2023 $ / shares	Mar. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized					500,000,000	500,000,000					500,000,000
Common stock, par value | $ / shares					$ 0.001	$ 0.001					$ 0.001
Shares of common stock sold							7,824,727
Warrants, exercise price per share | $ / shares					$ 2.32	$ 2.32			$ 2.51	$ 5.40	$ 6.49
Preferred stock, shares authorized					50,000,000	50,000,000					50,000,000
Preferred stock, par value | $ / shares					$ 0.001	$ 0.001					$ 0.001
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares authorized					12,000,000	12,000,000					12,000,000
Preferred stock, par value | $ / shares					$ 0.001	$ 0.001					$ 0.001
Preferred stock, shares outstanding					3,000,000	3,000,000					0
H.C. Wainwright & Co. LLC
Class of Stock [Line Items]
Letter agreement, payments of cash fee credit | $				$ 100,000
Percentage of cash fee paid under the letter agreement				3%
Securities Purchase Agreement
Class of Stock [Line Items]
Common stock, shares authorized			3,866,666
Shares of common stock sold			3,866,666
Shares Issued, Price Per Share | $ / shares			$ 0.75
Warrants, exercise price per share | $ / shares			$ 0.75
Warrants expiration term			5 years
Proceeds from issuance of Common stock, net of transaction costs | $			$ 2,900,000
Securities Purchase Agreement June Investors
Class of Stock [Line Items]
Common stock, shares authorized		9,670,002
Shares of common stock sold		9,670,002
Shares Issued, Price Per Share | $ / shares		$ 0.65
Warrants, exercise price per share | $ / shares		$ 0.6525
Warrants expiration term		5 years
Proceeds from issuance of Common stock, net of transaction costs | $		$ 5,710,000
Securities Purchase Agreement June Investors | H.C. Wainwright & Co. LLC
Class of Stock [Line Items]
Securities purchase agreement, placement agent fee percentage		6.50%
Less: transaction costs and advisory fees allocated to NRXP equity | $		$ (600,000)
Securities purchase agreement, august investors
Class of Stock [Line Items]
Number of shares issued	3,000,000
Number of warrants issued with each share | $					1
Proceeds from offering | $					$ 1,200,000
Aggregate cash purchase price per unit | $ / shares					$ 0.40
Securities purchase agreement, august investors | Series A Convertible Preferred Stock
Class of Stock [Line Items]
Warrants expiration term	5 years
Preferred stock, shares authorized								12,000,000
Preferred stock, par value | $ / shares	$ 0.001
Number of shares issued	3,000,000				3,000,000
Number of warrants issued with each share | item	1
Preferred stock conversion, stock price trigger | $ / shares						$ 1.20
Preferred stock conversion, period during which shares shall not be converted						6 months
Preferred stock conversion, threshold maximum percentage of outstanding common stock shares					4.90%	4.90%
Shares issued upon conversion					0	0

Equity - Substitute Warrants (D

Equity - Substitute Warrants (Details) $ in Thousands		3 Months Ended		9 Months Ended
	May 24, 2021	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Class of Stock [Line Items]
Change in fair value of warrant liabilities		$ (26)	$ 37	$ (27)	$ (236)
Merger agreement
Class of Stock [Line Items]
Exchange Ratio	3.16
Merger agreement | Stockholders of NeuroRx
Class of Stock [Line Items]
Exchange Ratio				3.16
Substitute Warrants
Class of Stock [Line Items]
Change in fair value of warrant liabilities			$ (100)		$ (100)
Substitute Warrants | Maximum
Class of Stock [Line Items]
Change in fair value of warrant liabilities				$ 100

Equity - Assumed Public Warrant

Equity - Assumed Public Warrants (Details) - $ / shares	21 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Number of outstanding warrants	33,021,591	30,021,591	20,351,589	16,484,923
Warrants, exercise price per share	$ 2.32	$ 2.51	$ 5.40	$ 6.49
Public Warrants
Class of Stock [Line Items]
Number of outstanding warrants	3,450,000
Number of shares per warrant	1
Warrants, exercise price per share	$ 11.50
Warrants expiration term	5 years
Warrants exercised during period	0

Equity - Assumed Placement Warr

Equity - Assumed Placement Warrants (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Number of outstanding warrants	33,021,591		33,021,591		30,021,591	20,351,589	16,484,923
Change in fair value of warrant liability	$ 26	$ (37)	$ 27	$ 236
Placement Warrants
Class of Stock [Line Items]
Number of outstanding warrants	136,250		136,250
Change in fair value of warrant liability				$ 200
Placement Warrants | Maximum
Class of Stock [Line Items]
Change in fair value of warrant liability	$ 100	$ 100	$ 100

Equity - Investor Warrants (Det

Equity - Investor Warrants (Details)					9 Months Ended
	Aug. 28, 2023 USD ($) $ / shares shares	Jun. 06, 2023 USD ($) $ / shares shares	Jun. 03, 2023 USD ($) $ / shares	Mar. 08, 2023 USD ($) $ / shares shares	Sep. 30, 2022 shares	Sep. 30, 2023 $ / shares	Jun. 30, 2023 $ / shares	Mar. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares	Feb. 28, 2022 $ / shares	Aug. 31, 2021 $ / shares
Class of Warrant or Right [Line Items]
Common stock and warrants issued, net of issuance costs (in shares) | shares					7,824,727
Warrants, exercise price per share						$ 2.32	$ 2.51	$ 5.40	$ 6.49
Exercise price per share
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input | $				0.75
Securities Purchase Agreement
Class of Warrant or Right [Line Items]
Common stock and warrants issued, net of issuance costs (in shares) | shares				3,866,666
Price per unit				$ 0.75
Expected term				5 years 6 months
Fair value on the date of issuance | $				$ 2,400,000
Warrants, exercise price per share				$ 0.75
Securities Purchase Agreement | Stock price on valuation date
Class of Warrant or Right [Line Items]
Price per unit				0.72
Securities Purchase Agreement | Exercise price per share
Class of Warrant or Right [Line Items]
Exercise price				$ 0.75
Securities Purchase Agreement | Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input				123.6
Securities Purchase Agreement | Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input				4.34
Securities Purchase Agreement | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input				0
Securities Purchase Agreement June Investors
Class of Warrant or Right [Line Items]
Common stock and warrants issued, net of issuance costs (in shares) | shares		9,670,002
Price per unit		$ 0.65
Warrants, exercise price per share		0.6525
June Placement Agent Warrants
Class of Warrant or Right [Line Items]
Exercise price		$ 0.81
Fair value on the date of issuance | $		$ 100,000
June Placement Agent Warrants | Stock price on valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		0.53
June Placement Agent Warrants | Exercise price per share
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		0.81
June Placement Agent Warrants | Expected life
Class of Warrant or Right [Line Items]
Expected term		5 years 6 months
June Placement Agent Warrants | Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		175.1
June Placement Agent Warrants | Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		3.85
June Placement Agent Warrants | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		0
Amended Warrants
Class of Warrant or Right [Line Items]
Exercise price		$ 0.6525
June Investor Amended Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price										$ 12	$ 3.07
Expected term		5 years 6 months	5 years 6 months
Warrants fair value disclosure | $			$ 1,700,000
June Investor Amended Warrants [Member] | Maximum
Class of Warrant or Right [Line Items]
Common stock and warrants issued, net of issuance costs (in shares) | shares		9,622,778
June Investor Amended Warrants [Member] | Stock price on valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input			0.53
June Investor Amended Warrants [Member] | Exercise price per share
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input			0.65
June Investor Amended Warrants [Member] | Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input			175.1
June Investor Amended Warrants [Member] | Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input			3.85
June Investor Amended Warrants [Member] | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input			0
Securities purchase agreement, august investors
Class of Warrant or Right [Line Items]
Fair value on the date of issuance | $	$ 800,000
Aggregate number of warrants issued | shares	3,000,000
Number of shares issued | shares	3,000,000
Securities purchase agreement, august investors | Stock price on valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.30
Securities purchase agreement, august investors | Exercise price per share
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.40
Securities purchase agreement, august investors | Expected life
Class of Warrant or Right [Line Items]
Expected term	5 years
Securities purchase agreement, august investors | Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	175.1
Securities purchase agreement, august investors | Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	4.38
Securities purchase agreement, august investors | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0

Equity - Schedule of Warrant Ac

Equity - Schedule of Warrant Activity (Details) - $ / shares	3 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Total Warrants
Outstanding at the beginning	30,021,591	20,351,589	16,484,923
Issued	3,000,000	9,670,002	3,866,666
Outstanding at the end	33,021,591	30,021,591	20,351,589	16,484,923
Weighted Average Remaining Term
Outstanding	4 years 3 months 10 days	4 years 4 months 9 days	3 years 7 months 24 days	3 years 7 months 2 days
Issued (in years)	4 years 11 months 1 day	4 years 11 months 8 days	4 years 8 months 8 days
Weighted Average Exercise Price
Outstanding at the beginning (in dollars per share)	$ 2.51	$ 5.40	$ 6.49
Issued (in dollars per share)	0.40	0.65	0.75
Outstanding at the end (in dollars per share)	$ 2.32	$ 2.51	$ 5.40	$ 6.49

Stock-Based Compensation - 2016

Stock-Based Compensation - 2016 Omnibus Incentive Plan (Details)	May 24, 2021 $ / shares shares	Sep. 30, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase shares of common Stock		2,548,849	2,548,849
Exercise price | $ / shares		$ 3.32	$ 3.32
Merger agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exchange Ratio	3.16
Options to purchase shares of common Stock	2,895,423
Exercise price | $ / shares	$ 5.10
2016 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance		3,472,000

Stock-Based Compensation - 2021

Stock-Based Compensation - 2021 Omnibus Incentive Plan (Details) - 2021 Omnibus Incentive Plan	9 Months Ended
	Sep. 30, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance	6,713,608
Number of additional shares authorized	664,430
Percentage of outstanding shares for determination of annual additional shares authorization	1%
Number of shares awarded	5,749,394
Number of shares available for issuance	964,214

Stock-Based Compensation - Opti

Stock-Based Compensation - Option Awards, assumptions (Details) - Stock Options - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price minimum		$ 0.51
Exercise price maximum		$ 3.10
Risk-free rate of interest, minimum		1.80%
Risk-free rate of interest, maximum		4.36%
Dividend yield	0%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)		5 years 3 months 18 days
Expected stock price volatility		94.90%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)		6 years 6 months
Expected stock price volatility		147.80%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of stock option activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Number of shares
Outstanding at the beginning (in shares)	2,548,849
Outstanding at the end (in shares)	2,548,849	2,548,849
Options vested and exercisable (in shares)	2,022,085
Weighted average exercise price
Outstanding at the beginning (in dollars per share)	$ 3.32
Outstanding at the end (in dollars per share)	3.32	$ 3.32
Options vested and exercisable (in dollars per share)	$ 3.68
Weighted average remaining remaining term (in years)
Outstanding (in years)	7 years 7 months 6 days	8 years 4 months 24 days
Options vested and exercisable (in years)	7 years 3 months 18 days
Aggregate intrinsic value
Outstanding at the beginning (in dollars)	$ 618
Outstanding at the end (in dollars)	10	$ 618
Options vested and exercisable	$ 10

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation		$ 0.8
Weighted-average period		7 months 6 days
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value	$ 0.64		$ 1.55

Stock-Based Compensation - Reco

Stock-Based Compensation - Recognition of stock-based compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 351	$ 541	$ 1,590	$ 2,862
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	261	506	1,295	2,390
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 90	$ 35	$ 295	$ 472

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-average period			7 months 6 days
Stock-based compensation expense	$ 351	$ 541	$ 1,590	$ 2,862
Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Balance, beginning of period			1,000,000
Shares vested			333,333
Balance, end of period	666,667		666,667
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Grant date fair value, beginning of period			$ 0.57
End of period	$ 0.57		$ 0.57
Unrecognized compensation, restricted stock	$ 300		$ 300
Weighted-average period			1 year 9 months 18 days
Stock-based compensation expense			$ 200
Maximum | Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock-based compensation expense	$ 100

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Liabilities:
Warrant liabilities	$ 10	$ 37
Recurring basis | Level 1
Assets:
Money Market Account	7,034	15,249
Recurring basis | Level 3
Liabilities:
Warrant liabilities	10	37
Convertible note payable (Note 7)	$ 10,069	$ 10,525

Fair Value Measurements - Conve

Fair Value Measurements - Convertible Note Liability (Details) - Recurring basis - Level 3	Sep. 30, 2023 $ / shares Y
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0
Convertible notes payable | Stock price on valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input | $ / shares	0.26
Convertible notes payable | Time to expiration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input | Y	0.59
Convertible notes payable | Note market interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.084
Convertible notes payable | Equity volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.900
Convertible notes payable | Volume volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	3.650
Convertible notes payable | Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.0552
Convertible notes payable | Probability of default
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.032

Fair Value Measurements - Con_2

Fair Value Measurements - Convertible Note Payable (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Par value of the Note	$ 11,020	$ 11,020	$ 11,020
Debt discount	(497)	(497)	(1,000)
Change in fair value of convertible note payable	359	2,794	505
Fair value adjustment through accumulated other comprehensive income		22
Convertible notes payable | Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Par value of the Note	11,020	11,020	11,020
Debt discount	(497)	(497)	(1,000)
Repayment of Principal		(3,270)
Carrying value of the Note before current period change in fair value	7,253	7,253	10,020
Change in fair value of convertible note payable		2,794	505
Fair value adjustment through accumulated other comprehensive income		22
Total carrying value of Note	10,069	10,069	10,525
Convertible note payable - current portion	$ 10,069	$ 10,069	7,703
Convertible note payable, net of current portion			$ 2,822

Fair Value Measurements -Schedu

Fair Value Measurements -Schedule of Measure the warrant liabilities (Details)	Sep. 30, 2023 $ / shares Y	Mar. 08, 2023 USD ($)
Exercise price per share
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input | $		0.75
Recurring basis | Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0
Recurring basis | Level 3 | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0
Recurring basis | Level 3 | Convertible notes payable | Stock price on valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.26
Recurring basis | Level 3 | Convertible notes payable | Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.0552
Recurring basis | Minimum | Level 3 | Stock price on valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.26
Recurring basis | Minimum | Level 3 | Exercise price per share
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	3.48
Recurring basis | Minimum | Level 3 | Expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input | Y	0.02
Recurring basis | Minimum | Level 3 | Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.550
Recurring basis | Minimum | Level 3 | Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.0379
Recurring basis | Minimum | Level 3 | Fair value of warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0
Recurring basis | Maximum | Level 3 | Stock price on valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.66
Recurring basis | Maximum | Level 3 | Exercise price per share
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	11.50
Recurring basis | Maximum | Level 3 | Expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input | Y	3.15
Recurring basis | Maximum | Level 3 | Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.751
Recurring basis | Maximum | Level 3 | Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.0540
Recurring basis | Maximum | Level 3 | Fair value of warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	79.34

Fair Value Measurements - Recon

Fair Value Measurements - Reconciliation of warrant liabilities (Details) - Common stock warrants - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at the beginning	$ 36	$ 25	$ 37
Gain upon re-measurement	$ (26)	$ 11	$ (12)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Nonoperating Income (Expense)	Nonoperating Income (Expense)	Nonoperating Income (Expense)
Balance at the end	$ 10	$ 36	$ 25

Income Taxes (Details)

Income Taxes (Details) $ in Thousands	21 Months Ended
	Sep. 30, 2023 USD ($)
Income Taxes
Provision or benefit for income tax expense	$ 0

Related Party Transactions (Det

Related Party Transactions (Details) $ in Millions			3 Months Ended		9 Months Ended
	Mar. 29, 2023 shares	Nov. 06, 2022 USD ($) D	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	May 29, 2023 USD ($)	Dec. 31, 2022 USD ($)
Related Party Transaction [Line Items]
Minimum equity required for transfer of Excluded Technology		$ 50
Number of consecutive trading days | D		20
Number of trading days | D		20
Threshold aggregate liquidity of the related party							$ 0.6
Consulting fee payable per month							0.1
Performance based annual bonus minimum target							$ 0.3
2016 Omnibus Incentive Plan
Related Party Transaction [Line Items]
Shares granted | shares	500,000
Number of shares, restrictions removed on new drug application date | shares	(250,000)
Number of shares, restrictions removed on new drug approval date | shares	(250,000)
Former CEO
Related Party Transaction [Line Items]
Payment to related party			$ 0.2	$ 0.2	$ 0.7	$ 0.7
Chief Executive Officer Son [Member]
Related Party Transaction [Line Items]
Payment to related party			0.1		0.1	0.1
Chief Executive Officer Son [Member] | Maximum
Related Party Transaction [Line Items]
Payment to related party				0.1
Related Party [Member] | Maximum
Related Party Transaction [Line Items]
Accounts payable due to related parties			0.1		0.1			$ 0.1
Glytech Agreement [Member]
Related Party Transaction [Line Items]
Payment to related party			$ 0.1	$ 0.1	0.2	0.2
PillTracker SOW
Related Party Transaction [Line Items]
Payment to related party					$ 0	$ 0.2